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ABSTRACT
Pancreatic cancer (PC) is the 4th leading cause of cancer in the US and the survival rate
beyond 5 years is below 9%; the lowest of any cancer1. Pancreas and liver cancers are projected
to surpass breast, prostate, and colorectal cancers to become the second and third leading causes
of cancer-related death by 2030, respectively2. There are two types of pancreatic cancer: exocrine
tumors (the tumor happens where the cells produce enzyme to digest food) and endocrine tumors
(the tumor happens where the cells produce insulin to regulate blood sugar). About 95 percent of
pancreatic cancers begin in the exocrine cells of the pancreas3.
The causes of pancreatic cancer remain unknown, tobacco, alcohol, family history and high
-cholesterol diet are contributing factors. The progression from normal epithelium to pancreatic
cancer begins with the accumulation of activation of oncogene KRAS and then inactivation of
tumor suppressor genes—for example p16 (also known as CDKN2A), SMAD4 (also known as
DPC4), and p53 (also known as TP53)4-5 evolve via pancreatic intraepithelial neoplasias (PanINs).
KRAS mutations is responsible for 75-90% of pancreatic cancer patients and start very early in the
development of pancreatic cancer6-9. The well-validated role of mutationally activated RAS genes
in driving cancer development and growth has stimulated comprehensive efforts to develop
therapeutic strategies to block mutant RAS function for cancer treatment. Disappointingly, despite
more than three decades of research effort, clinically effective anti-RAS therapies have remained
elusive, prompting a perception that RAS may be undruggable10.
PC is usually diagnosed by a combination of medical imaging techniques such
as ultrasound computed tomography, CT scan with IV contrast, blood tests, and examination of
tissue samples (biopsy). At this time, the best progress for this disease is to diagnose in the early
stages. Phenomics is an branch of biology responsible for the measurement of phenomes—the
4

physical and biochemical characteristic of organisms as they change correlated to

genetic

environmental factors11. Traditional biological experiments, such as GWA (genome-wide
association) studies, is selecting a phenotype and then attempting to associate biological
differences within a population. The unequivocal phenotype is what patients and clinicians wish
to predict. At present, none phenomics studies have been applied to drug therapy. Detailed
electronic medical record (EMR) data will allow for large-scale phenomics studies, when paired
with GWA studies or other biological databases12. Metabolomes are defined as all compounds
generated by living organisms during their life cycles and reflect the function of the organisms as
a whole13. Metabolomics analysis can be applied to both in vitro and in vivo specimens by using
body fluids, cells or tissues. Comparing the different result of metabolomics analysis of the
pancreatic cancer patient and healthy people can provide the reference of the detection of
pancreatic cancer. The two most popular techniques are nuclear magnetic resonance spectroscopy
(NMR) and mass spectrometry (MS) coupled with gas chromatography, liquid chromatography or
capillary electrophoresis.14-16 Although cross sectional imaging tests such as abdominal ultrasound
(US), computerized tomography (CT-scan), magnetic resonance imaging (MRI), endoscopic
ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP) have been
developed to detect the disease, none of them works for the early stage tumor.17-19 Biomarkers lack
enough specificity to make difference between PC and diseases such as pancreatitis and
cholangitis.17 Since no single molecule has been shown to be specific enough for the discrimination
of patients with early PC, some study groups have used multiple logistic regression analysis to
compare PC patients with healthy controls. a statistical diagnostic model was generated.20 In
addition to serum, other biofluids such as bile and pancreatic fluids have been used to study
metabolic profiles for the diagnosis of early PC.21 The saliva metabolites profiles showed higher
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concentrations of most of the metabolites detected in pancreatic, breast and oral cancer compared
with those with periodontal disease and control diseases. This result indicates that cancer-specific
signatures are contained in saliva metabolites. Multiple logistic regression models showed high
area under the receive operating characteristic curves (AUCs) to discriminate healthy controls
from each disease. The AUCs were 0.993 for pancreatic cancer, and 0.969 for periodontal diseases.
The accuracy of the models was also high, with cross-validation AUCs of 0.994, and 0.954,
respectively. Even these correlations significant and promising, but they are small and not
sufficient to change current clinical practice and more studies are needed.21-22 No diagnostic tests
for the screening of pancreatic cancer has been identified thus far and none of the biomarkers has
yet to be proven useful for this purpose17. Genomics is a discipline in genetics that applies
recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and
analyze the function and structure of genomes.23 Genetics represents a constant in any biological
system compared with metabolomes and phenomics. DNA of the healthy individuals and
pancreatic cancer patients were analyzed, and it was found that pancreatic cancers contain an
average of 63 genetic alterations, most of them point mutations. These alterations defined a core
set of 12 cellular signaling pathways and processes that were each genetically altered in 67 to 100%
of the tumors24.
Surgery is the only possibility for a curative treatment but is a limited option only available
to 15-20% of PC patients present with localized and potentially curable tumors25. As a result,
chemotherapy and radiation therapy plays an important role throughout PC treatment. Radiation
therapy is quite helpful for treating the exocrine cancer and, it can help relieve the patients’ pain.
In patients not suitable for curative surgery, chemotherapy and radiationtherapy are primary ways
to extend life or improve its quality. Endocrine cancer does not respond well to radiation therapy.
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What is more it will cause unpleasant side effects such as skin changes, fatigue, nausea, and other
side-effects26. Currently, there are four major first-line drugs approved for the treatment of
pancreatic cancer: FOLFIRINOX, erlotinib, gemcitabine, and mitomycin C. There are also other
drugs, like Platinum agents (Cisplatin and Oxaliplatin), humanized antibody Keytruda, and
Taxanes. FOLFIRINOX and gemcitabine act by replacing pyrimidine and cytidine, respectively,
during the biosynthesis of nucleic acids and DNA replication. As a result, tumor growth is arrested
by false nucleoside incorporation induced cell death. As compared with gemcitabine,
FOLFIRINOX was associated with a survival advantage and had increased toxicity.
FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good
performance status26. Mitomycin C, oxaliplatin and cisplatin are DNA cross-linking agents, which
can react with two different positions in DNA, halt DNA synthesis and lead to apoptosis27.
Erlotinib is a small molecule human epidermal growth factor receptor 1/epidermal growth factor
receptor (HER1/EGFR) tyrosine kinase inhibitor, preventing the growth factor and receiver from
being phosphorylated, effectively disrupting the signaling pathway28. The molecular action of
irinotecan occurs by trapping a subset of topoisomerase-1-DNA cleavage complexes, leading to
inhibition of both DNA replication and transcription29. The principal mechanism of action of the
taxane class of drugs is the disruption of microtubule function27. Keytruda used in cancer
immunotherapy, can block protective mechanism of cancer cells and thereby, allows the immune
system to destroy them30. However, regardless of whether these drugs are used alone or in
combination, none have been effective in significantly improving overall survival rates. This
disparity, compared to other cancer types, has led to the projection that pancreatic cancer will
become the second most deadly cancer in the United States by 2030, surpassed only by lung
cancer31. Any improvements in treatment will come as a much-needed reprieve to patients
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diagnosed with this uniquely-challenging and lethal disease. Advances will come from more
effective and specific chemotherapeutic agents. The marine environment with its exceptional
biodiversity has yielded diverse chemical space and serves as a rich source of novel compounds
with significant therapeutic promise. Discorhabdin alkaloids are the main metabolites of
Latrunculia sponge and all the published discorhabdins showed different ranges of cytotoxicity to
different cancer cells.32 Thus, we hypothesis that new discorhabdins from Latrunculia sponge
could be a lead for pancreatic cancer. Instead of isolating strictly using other low-throughput
chemical techniques or bioassays alone which is time consuming, Molecular Ion
Networking (MoIN) to isolate new and novel compounds was applied. A new class of
pyrroloiminoquinone alkaloids possessing a highly strained multi-bridged ring system, discovered
from Latrunculia (Latrunculia) austini Samaai, Kelly & Gibbons, 2006 (class Demospongiae,
order Poecilosclerida, family Latrunculiidae) recovered during a NOAA deep-water exploration
of the Aleutian Islands. The molecule was identified with the guidance of MS, NMR, and
Molecular Ion Networking (MoIN) analysis. The structure of aleutianamine was determined using
extensive spectroscopic analysis in conjunction with computationally-assisted quantifiable
structure elucidation tools. Aleutianamine exhibited potent and selective cytotoxicity toward solid
tumor cell lines including PC(PANC-1) with an IC50 of 25 nM and colon cancer (H116) with IC50
of 1 µM and represents a potent and selective candidate for advanced preclinical studies.
Plant-microbiome association studies have revealed a unique relationship between the host
plants and their microbiome. This relationship involves significant benefits for the plant through
protection from fungi, bacteria, herbivores and insects; however, at the same time overgrowth of
an endophyte can cause harm to the plant33. The role of natural products in microbiome-plant
associations and the overall success of plants remains a highly complex and relatively unexplored
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field34-35. We serendipitously discovered that plant microbiome Bacillus. amyloliquefaciens
cultured from American sycamore produced rapamycin and was regulated seasonally and plant
organ specific differently by platanoside isolated from American sycamore (Platanus occidentalis
L.). Although that B. amyloliquefaciens generates diversity of metabolites from polyketides to
triterpenes, influence many expects from pathogenic defense to growth promotion, B.
amyloliquefaciens generating rapamycin and regulated by host metabolites was expected. Here,
we show that previously characterized rapamycin was generated by B. amyloliquefaciens
inhabiting in xylem of American sycamore. We demonstrate that the potent antibiotics
platanosides found in the healthy sycamore leaves appear to play a clear regulator function of the
B. amyloliquefaceins. It has been reported that when the Target of Rapamycin (TOR) is inhibited
in plants treated with rapamycin, it will promote autophagy of the cells and differentiation of xylem
tracheary elements as well as extend the life-expectancy of the plant36. These results revealed that
rapamycin generated by B. amyloliquefaciens appears to play a key role in the development of
vascular tissue to transport water in this species of tree, promote autophagy of autumn leaves thus
recovering nutrients and contribute to sycamore unique longevity. It also displayed how P.
occidentalis controls the growth of B. amyloliquefaciens subsp. plantarum through the
concentration of platanoside to avoid the potential harm caused by the overgrowth of B.
amyloliquefaciens subsp. plantarum. The metabolites from endophytes and hosts mediate the
interaction to realize the success of this species.
The chronic liver disease caused by xenobiotics and viral infection will eventually lead to
liver cancer; the second most common cancer in the world. In 2018, WHO reported that around
788,000 people die from primary liver cancer every year. It is also reported that from 1999 to 2015,
deaths from liver cancer in the US increased by 60% while deaths from other cancers decreased

9

by 26%. Levels of both hepatitis testing and treatment are still extremely low in most regions of
the world drugs still play a vital role in controlling liver disease. Highly oxygenated triterpenoids
and dibenzocyclooctadiene lignans isolated from plants of the genera Schisandra and Kadsura
have revealed a variety of important biological activities including potent anti-HIV 37, anti-HBV
38

, and cytotoxic properties39-42. Two clinically used drugs for liver disease dimethyl bicarboxylate

and bicyclol are the structurally modified molecules isolated from Schisandra and Kadsura. We
hypothesized that unreported hepatoprotective triterpenoids and dibenzocyclooctadiene lignans
from Kadsura can be drug candidates for the liver disease. Their 2D structures and relative
configurations have been successfully elucidated by NMR spectroscopic methods. Assignment of
their absolute configurations is critical since it influences their bioactivities and is essential for
future efforts focused on synthesis and medicinal chemistry applications. Herein, we report an
integrated analysis to comprehensively assign the absolute configurations of four new schiartanetype nortriterpenoids and three novel dibenzocyclooctadiene lignans using a combination of
methods.
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Scheme 2. Putative Biosynthesis Pathway Towards the Formation of 5–7.
Scheme 3. Biotrasformation of discorhabdin A to aleutianamine.
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CHAPTER ONE
COMPUTATIONALLY-ASSISTED DISCOVERY AND ASSIGNMENT OF A HIGHLY
STRAINED AND PANC-1 SELECTIVE ALKALOID FROM ALASKA’S DEEP OCEAN
Published in J. Am. Chem. Soc. 2019, 10, 4338; Accepted in Journal of Oncology and Cancer.
Research

Efficient Procedure to Target and Purify Active Metabolites

Latrunculia sp.

MoIN directed discovery

Targeted purification of
potent and selective antiPANC-1 novel compound

1. Introduction:
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Distinguished by an extremely low five-year survival rate of 8% in the United States,
PC(PC) represents a significant public health issue rife with challenges43. Due to poor prognoses
relative to other cancers, PC is the seventh highest cause of cancer-related death worldwide and
ranks fifth in the United States based on the CDC despite being a relatively uncommon form of
cancer in regard incidence rates. PC causing over 330,000 deaths worldwide in 2012 44-45. The
efficacy of PC treatment has changed little over time as a result of difficulties in diagnosis and
poor response to chemo- and radiation -therapies. This disparity, compared to other cancer types,
has led to the projection that PC will become the second most deadly cancer by 2030, surpassed
only by lung cancer2. Any improvements in treatment will come as a much-needed reprieve to
patients diagnosed with this uniquely-challenging and lethal disease.
Treatment options for PC, as with most cancers are highly dependent on the stage at the
moment of diagnosis; for PC patients, surgery is currently the only potentially curative treatment,
but is limited to only 15-20% of patients, largely due to the high rate of metastasis46. As a result,
chemotherapy and radiation therapy play an important role throughout PC treatment. Some of the
current PC chemotherapeutics like gemcitabine were developed to target some of the very gene
mutations used in tracking the disease like BRCA1 and BRCA247. For patients suitable for surgery,
these treatments can be used pre- or post-operation to reduce the risk of further tumor growth,
spread or recurrence. Additionally, for patients not suitable for surgery, chemo-, and radiation
therapy are the primary treatment options to extend and improve the quality of life. However, the
use of radiation therapy in PC patients has been controversial and is most efficacious when
performed in tandem with chemotherapy, which has been shown to improve patient outcome
alone48-49. This lends credence to the assertion that increasing the chemotherapeutic options for the
treatment of PC is a critical strategy in addressing this global public health issue. Currently, there
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are four major first-line drugs approved for the treatment of pancreatic cancer: fluorouracil,
erlotinib, gemcitabine, and mitomycin C (Fig.1). Fluorouracil and gemcitabine act by replacing
pyrimidine and cytidine, respectively, during the biosynthesis of nucleic acids and DNA
replication. As a result, tumor growth is arrested by false nucleoside incorporation induced cell
death. Mitomycin C is a DNA cross-linking agent, which can react with two different positions in
DNA, halt DNA synthesis and lead to apoptosis. Erlotinib is a small molecule human epidermal
growth factor receptor 1/epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor,
preventing the growth factor and receiver from being phosphorylated, effectively disrupting the
signaling pathway28. However, regardless of whether these drugs are used alone or in combination,
none have been effective in significantly improving overall survival rates.

Figure 1. First-line drugs used for the treatment of pancreatic cancer4.
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Natural products have provided valuable drugs to treat cancer and to assist in a better
understanding of this disease.50-52 It has been estimated that up to 50% of all present medicines
have been derived from natural products, and in the case of cancer, this is near 75%.53-54 The plant
derived paclitaxel, one of the most highly documented chemotherapeutic from a natural source,
with marine invertebrates provided lead molecules such as halichondrin B, didemnin B, and
dolastatins, are in various stages of development.55-57 More recently, marine organisms have
demonstrated a great potential for discovery of anticancer drugs, including bacteria and fungi
(salinosporamide A and dolastatins), tunicates (didemnin B) and sponges (halichondrin B).58
Among these marine derived anti-tumor agents, pyrroloiminoquinone alkaloids have been studied
for decades.32, 59-60 The pyrroloiminoquinone alkaloids exhibit strong cytotoxicity toward different
types of tumor cell lines.61-62 The potent activities and unique structures have resulted in several
total syntheses63-65 and biosynthetic studies.66-69
Our recent discovery of new discorhabdins70 and related metabolites71 from the Alaskan
sponge Latrunculia sp. prompted a recollection during a NOAA deep ocean survey to facilitate
the discovery of natural analogues. Identification of unknown molecules, early in the NP workflow
minimizes time, effort, and cost.72 Current dereplication strategies include HPLC-MS, HPLCNMR, and HPLC-NMR-MS.73-74 However, a full elucidation either occurs late in the workflow or
otherwise remains elusive. Mass spectrometry based dereplication is critical to modern natural
product dereplication pipelines which is more sensitive and easier to interpret than NMR. however,
it is often difficult to reliably dereplicate a given compound when solely using precursor or parent
masses because of the number of results. However, MS/MS data are definitive characteristics of a
molecule and thus could be effectively used in dereplication. The underlying assumption of MS
together with MS/MS-based dereplication is that structural architecture, chemical stability, and
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functional groups combine to dictate reactivity by collision-induced dissociation

As an efficient

protocol recently developed for the discovery of new natural products, networking analysis enables
visualization of observed molecules as familial groupings in which commonalities within the MS
fragmentation data are assessed via vector correlations and displayed as an MS/MS network.75 The
visualization of networks by using Cytoscape enable the direct observation of similarities as well
as differences between two or more samples in which similar entities within the network are
clustered together while disparate or unique entities are grouped separately.76 In this manner, initial
discovery of unknown substances was facilitated.
Further exploration now calls for well-defined chemical structures. Single crystal X-ray
diffraction analysis remains the most straightforward approach in the structure elucidation of novel
compounds.77 However, a crystal that diffracts well is not always easily obtained. NMR
spectroscopic analysis continues to be the most widely applied approach for structure elucidation
albeit challenging when applied to architecturally unique molecules. In the latter cases,
computational chemistry, in conjugation with spectroscopic methods, provides a powerful tool for
the assignment of atom connectivity, relative, and absolute configurations of complex
molecules.78-79 Highly noteworthy is the protocol developed recently by Martin, Williamson, et
al.77 incorporating anisotropic NMR parameters with computational approaches to determine the
structures of complex natural products. Atom connectivity and stereochemical assignment using
NMR chemical shift calculation tools, such as GIAO calculation/DP4+ probability,80-81 also allows
accurate

prediction

of

the

real

structure

among

otherwise

possible

constitutional

isomers/diastereomers. Excited-state calculation methods such as TDDFT have been widely
applied in conjunction with experimental ECD spectroscopy to determine the absolute
configurations of natural products.82-84 We report herein a new protocol that involves the
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compound discovery and orchestration of different computation methods in combination with
spectroscopic analyses that together led to the establishment of a well-defined molecular structure
of aleutianamine.

Sample extract

GNPS

“Seed” MS/MS of known

+

LCMS/MS
analyzing

Networking

Visualize
the data
Analyze data,
target
and
purify

Pick out the
active analogs
cluster

Figure 2. General procedure to implement molecular networking for dereplication. Experimental MS/MS
spectra of samples, and MS/MS spectra of known molecules are analyzed by GNPS. The resultant network
is visualized in Cytoscape.

2. Materials and Methods
2.1 Extraction and purification
Four kilograms of frozen sponge was cut into 1-2 cm3 pieces followed by extraction with
ethanol assisted by ultrasonication at room temperature, affording about 225 g crude extract. This
extract was directly applied to flash silica gel VLC with gradient elution of n-hexane-ethyl acetate
(50:50, 0:100) followed by ethyl acetate-methanol (75:25, 50:50, 0:100) then methanol-water
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(50:50). The ethyl acetate-methanol (75:25, 50:50) fractions were combined and loaded on a
Sephadex LH-20 glass column with an elution system of dichloromethane-methanol (50:50) under
normal pressure. The Sephadex LH-20 fractions with MW range from 300-700 Daltons were
subjected to C18 medium pressure chromatography eluded with methanol-water (0.03%
trifluoroacetic acid) for crude separation. The fractions eluted with 10-60% methanol (large sets
of fractions were combined to acquire the crude mixture of different pyrroloiminoquinone
alkaloids) were further purified by using preparative HPLC (Phenomenex C18 column, 21.2 × 250
mm with flow rate at 8 ml/min; or C8 column, 10.0 × 250 mm with flow rate at 4 ml/min) with a
mobile phase of MeCN- H2O (0.05% trifluoroacetic acid) or MeOH- H2O (0.05% trifluoroacetic
acid) to yield aleutianamine (15 mg) and other known discorhabdins. (Fig. 3) Aleutianamine was
isolated as TFA salt with FTHRESIMS signals at 397.9959 [M]+ and 399.9937 [M+2]+ (calcd for
C18H13BrN3OS, 0.32 ppm) with a observed ratio of 1:1.2. CD (MeOH), λmax=224 nm (Δε +1.25),
λmax=268 nm (Δε -1.43), λmax=322 nm (Δε +0.46), λmax=378 nm (Δε -0.83), λmax=590 nm (Δε
+0.16). IR (film), v 3107, 2922, 1666, 1514, 1411, 1341, 1168, 1124, 995, 798, 718 cm-1.
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Figure 3: Isolation scheme of aleutianamine and other discorhabdin analogs.
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2.2 NCI samples MoIN analyzing. Each compound from six standards and the 10 crude ethanol
extracts of Latrunculia sp. from NCI were solubilized in 100% MeOH to 1mg/ml. The injected
samples were chromatographically separated using a Agilent analytical UHPLC (Santa Clara, CA)
using a 100 X 4.6 mm Kinetex 1.7 µM, C8, chromatography column (Phenomenex Torrance, CA),
1mL/min flow rate, mobile phase A 99.9% water (VWR, LC-MS grade) 0.1% formic acid (VWR),
mobile phase B 99.9% acetonitrile (VWR, LC-MS grade) 0.1% formic acid (VWR), with the
following gradient: 0-1 min 5% B, 1-15 min 100% B, 15-25 min, 100% B, 26-30 min, 5% B for
all samples.
Table 1. Ten Latrunculia sp collected in different places and their codes
Country

Family

Genus

Subgenera

Species

Northern New Zealand (Auckland)

Latrunculiidae

Latrunculia

Biannulata

procumbens

Northern New Zealand

Latrunculiidae

Latrunculia

Biannulata

procumbens

Southern New Zealand (Chatham)

Latrunculiidae

Latrunculia

Latrunculia

triverticillata

Southwestern Australia

Latrunculiidae

Latrunculia

Biannulata

purpurea

Southwestern Australia

Latrunculiidae

Latrunculia

Biannulata

purpurea

Northern New Zealand (Auckland)

Latrunculiidae

Latrunculia

Biannulata

kaakaariki

Antarctic (South Polar)

Latrunculiidae

Latrunculia

Latrunculia

biformis

Antarctic (South Polar)

Latrunculiidae

Latrunculia

Latrunculia

biformis

Southwestern Australia

Latrunculiidae

Latrunculia

Latrunculia

n. sp.

Northern New Zealand

Latrunculiidae

Latrunculia

Latrunculia

fiordensis
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Cape of Good Hope (Cape Province)

Latrunculiidae

Latrunculia

Alaska Island

Latrunculiidae

Latrunculia

Biannulata

lunaviridis

2.3 Molecular annotations. The annotation of compounds was done in two steps. First, the sample
data was subjected to automated dereplication work flow situated on Global Natural Products
Social Molecular Networking (GNPS) platform online (http://gnps.uscd.edu). The output table
with annotation was analyzed, annotations with corresponding retention times, m/z’s, ppm errors
were recorded and summarized in table. The manual annotation of unidentified signals in the
chromatogram of analyzed mixture was performed by matching of exact mass of compounds and
by comparing their MS/MS fragmentation spectra to the standards.
2.4 Molecular Networking. Raw data files were converted to the .mzXML format using
ProteoWizard sorftware and uploaded to the GNPS. Molecular networking parameters were as
follows: a minimum matched peaks threshold of 4, a cosine similarity score cutoff of 0.7, minimum
intensity of 800 and ion tolerance of 0.5 Da. Molecular networks were visualized and mined using
Cytoscape software.
2.5 Zone assay methodology. A volume of 15 µl of aleutianamine (2 mg/ml) is dropped onto a
65 mm disk. The disks are allowed to dry overnight and then placed close to the edge of the petri
dish. The plates are incubated for 7 days and examined by an inverted stereo-microscope for
measurement of the zone of inhibition of the colonies measured from the edge of the filter disk to
the beginning of control-size colony formation.the diameter of the disk is taken as 200 units. A
zone is less than 300 units is taken as the sample is of insufficient activity to be further interest. A
difference in zones between solid tumor and either normal or leukemia cell of 250 units or greater
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defines a solid tumor selective compound. When the sample was diluted 16-fold or greater to
obtain a zone of 500 units or more against any solid tumor cells, the sample is termed potent.
3. Result and discussion.
3.1 Analysis of MoIN of Latrunculia sp.
Figure Saaa Annotation of discorhabdins cluster MS/MS spectra of ten different Latrunculia sp.
the pink signals are discorhabdins standard identified by NMR. The orange signal is only observed
in the Latrunculia (Latrunculia) sp. nov. (Tasmania), the red signals are only observed in the
Latrunculia biformis Kirkpatrick, 1908, and the purple signal is only found in Alaska sponge
Latrunculia sp.

Figure 4. Annotation of discorhabdins cluster MS/MS spectra of 391.045. The MS/MS fragmentation,
precursor masses, and isotopic pattern for signal of 535.135 and 336.104 were highly suggestive of the
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known metabolite discorhabdins H2 and discorhabdins D respectively. The signal of 391.045 with different
retention time with discorhabdins H2 and discorhabdins D suggested new analogs. Based on the
fragmentations and molecular weight, the substituent group of the new discorhabdin should be -C2H4CN.
The putative structure is shown above.

c

535.135

249

b a

303 335

249

c

391.045

a
b 335

303

Figure 5. Annotation of discorhabdins cluster MS/MS spectra of 375.034, 376.04 and 376.024. The signals
of 375.034, 376.04 and 376.024. with same retention time with new discorhabdin with MW of 391.045
suggested these signals might be the fragments of 391.045 and the high cosine value (0.96) also indicated
they were almost identical. The raw MS/MS data of 391.045 also showed the signals of 375.034, 376.04
and 376.024, indicating they are fragments not the parent mass.
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Figure 6. Annotation of discorhabdins cluster MS/MS spectra of 429.999. The MS/MS fragmentation,
precursor masses, and isotopic pattern for signal of 416.489 were highly suggestive of the known metabolite
discorhabdins B. The signal of 429.999 with different retention time with discorhabdins B suggested new
analogs. Based on the fragmentations and molecular weight, there is an extra hydroxy group compared to
discorhabdins B. The putative structure is shown above.
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3.2 Structure elucidation of aleutianamine
To further explore this unknown molecule, large scale extraction and purification of the sponge
sample led to isolation of the potential target (m/z 398) resulted from MoIN analysis (vide supra)
as a green-yellow solid with the molecular formula of C18H13BrN3OS generated by high resolution
mass spectrometry analysis. The presence of 18 carbons was validated with 18 signals in a 13CNMR spectrum. A pyrroloiminoquinone moiety was initially proposed by comparing the aromatic
region of the
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C-NMR with the known natural product discorhabdin A.i The presence of this

moiety was further confirmed by the COSY correlation of H-16 with H-17, ROESY correlations
of H-14 with H-13 and H-16, and HMBC correlations indicated on Fig. 8. Interestingly, H-17b
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displayed an additional HMBC correlation with a tertiary carbon (δC 62.8) of which the attached
proton (δ 5.20, t, J=2.8) also displayed a HMBC signal to C17 (Fig. 8). This evidence suggested
that the later now C-3(δ 62.8) was connected to the pyrroloiminoquinone moiety likely via the
imine nitrogen (N-18). The presence of this connection was secured by the 1H-15N HMBC
correlation of H-4b (vide infra) to N-18 (δ 143.2). N-18 was thereby quaternary and positively
charged.
The frozen Alaskan sponge Latrunculia sp. was extracted and purified to afford aleutianamine as
a green-yellow TFA salt soluble in methanol and DMSO. An accurate molecular formula
C18H13BrN3OS was established based on the data acquired from FT-MS. The presence of 18
carbons was further validated with 18 signals in a 13C-NMR spectrum. The 13C NMR resonances
of C10 through C21 showed the pattern corresponding to a pyrroloiminoquinone scaffold85
represented by discorhabdin A, with the exception of C17 (δ 52.5) shifted 6-10 ppm downfield
which provided possible evidence for a positively charged nitrogen. The 13C NMR resonances of
other signals displayed a unique pattern that is differ from any other reported pyrroloiminoquinone
alkaloids.
The structure elucidation started with the arrangement of the six-membered ring constructed from
C1 through C6. COSY correlations of H4a and H4b linked H3; followed by the HMBC
correlations from both H4a and H4b to C5 and C6; in addition to H4a to C2 and C3; as well as H3
to C1, C2, C4 and C5; and H1 to C2, C3, C5, C6 and C7. An overlaid 13C-NMR spectrum with a
DEPT spectrum indicated that C6 (δ 141.4) was quaternary and was connected to the quaternary
C5 to close the six-membered ring. Therefore, C1 (δ 128.4) and C2 (δ 117.2) together with C6 and
C7 (δ 111.9) generated a conjugated diene moiety, and there was no detectable homonuclear
coupling constant for the H1 signal (δ 7.12). The olefinic carbon C2 (δ 117.2) was detected in the
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high field region because of the shielding effect of the bromine substitution. This assignment was
further supported by the isotope peak pattern acquired from the mass spectrum. The sevenmembered ring moiety was constructed from C5 to C8, N9, C10 and C21 beginning from the
COSY correlation of H7 and H8 followed by the HMBC correlations from H7 to C6, C5, C8 and
C21; as well as H8 to C6, C7 and C10, and finally confirmed by the HMBC from H4a, b to C21.
Sulfur incorporating is common in pyrroloiminoquinone alkaloids32 and also the case here. Based
on the formula generated by the FT-MS and the calculated double bond equivalent, the sulfur atom
was assigned as a thioether bridge and could only be placed between C5 (δ 48.7) and C8 (δ 64.6)
based on the carbon chemical shifts. This placement of the sulfur was further supported by a 3bond HMBC correlation from H8 to C5 through the thioether-bridge. The chemical shift of C3 (δ
62.8) suggested a possible connection to a heteroatom. Based on the calculated double bond
equivalent and the chemical shift, a covalent connection was established between C3 and N18 to
join the six-membered ring with the iminoquinone moiety to form yet another ring. The HMBC
correlations from H3 to C17 and C19 as well as H17b to C3 were detected to verify this connection.
Also, a 1H-15N HMBC experiment was performed to further confirm this connection in addition to
assessing the chemical environment of the positive charged nitrogen on the bridgehead. The
correlations from H4b, H16a and H17a to N18 were clearly observed. Notably, the signal of the
positive charged N18 indirectly detected at 143 ppm was more shielded than the tertiary N13 (δ
168).
Table 2. NMR data set of aleutianamine
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δC

δH (mult, J, Hz)

δC

δH (mult, J, Hz)

COSY

HMBC

ROESY

1

(in MeOD-d4)

(in MeOD-d4)

(in DMSO-d6)

(in DMSO-d6)

(in DMSO-d6)

(in DMSO-d6)

(in DMSO-d6)

(in DMSO-d6)

1

127.8

7.12, s

128.4

7.20, s

C-2, C-3, C-5, C-6, C-7

H-4b, H-7

2

116.7

3

63.4

5.12, t, J=2.9

62.8

5.20, t, J=2.8

H-4a, H-4b

C-1, C-2, C-4, C-5, C-17, C-19

H-4a, b, H-17a,b

4a

31.1

2.55, dd, J=2.2,12.7

31.4

2.50, dd, J=2.7, 12.7

H-3, H-4b

C-2, C-3, C-5, C-6, C-21

H-3, H-4b

2.60, dd, J=2.7, 12.7

H-3, H-4a

C-5, C-6, C-21

H-1, H-3, H-4a

Atom
No.

4b

117.2

2.65, dd, J=3,12.7

5

48.5

48.7

6

141.5

141.2

7

111.1

5.40, d, J=3.2

111.9

5.42, d, J=3.1

H-8

C-1, C-5, C-6, C-8, C-21 weak

H-1, H-8

8

64.0

5.96, d, J=3.3

64.6

6.02, brd, J=3.2

H-7

C-5, C-6, C-7, C-10

H-7, H-9

NH-9

N/A

10

140.8

140.9

11

167.2

167.9

12

124.3

124.5

NH-13

167.8 (15N)

14

125.2

15

118.0

16a

19.8

16b
17a

7.07, s

126.7

52.6

10.95, brs

H-8

13.12, s

H-14

7.24, s

N-18

C-11 weak, C-12, C-15, C-19 weak, C-20

H-16a,b, H-13

N-13

N-18

117.2
3.10, dt, J=4.2,16.2

20.3

3.22, m

17b

H-15N HMBC

4.24, dd, J=4.3, 10.5

52.5

4.26, dd, J=4.3, 10.5

N-18

143.2 (15N)

19

148.3

147.9

20

121.2

121.6

21

100.3

100.0

3.05, m

H-16b, H-17a, b

C-14, C-15, C-17, C-20

H-14, H-16b, H-17a,b

3.10, m

H-16a, H-17a, b

C-14, C-15, C-17, C-20

H-14, H-16a, H-17a,b

4.10, m

H-17b, H-16a, b

C-15, C-16, C-19

H-3, H-16a,b, H-17b

4.30, dd, J=6.0, 14.0

H-17a, H-16a, b

C-3, C-15, C-16, C-19

H-3, H-16a,b, H-17a

N-18
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The relative configuration and the three-dimensional structure were drafted by a ROESY
experiment and quantitatively trimmed by a computational approach (Fig. 8). H8 showed a strong
ROESY correlation solely with H7, and H7 showed an additional correlation with H1 verifying
H7 and H8 were vicinal to each other (J=3.1 Hz) and arranged on the seven-membered ring, and
H1 was thus located on the six-membered ring. On this bromine substituted six-membered ring
moiety, the correlations of H1 with H4b, and H4a,b with H3 were clearly observed. The ROESY
correlation between H4a and H1 was undetectable, which suggested H4a and H4b were placed on
the equatorial and axial positions, respectively, and this ring was in a stable half-chair
conformation. ROESY correlations of H3 with H17a and H17b were detected to further confirm
the connection between C3 and N18. In addition, the two exchangeable protons detected at 10.95
ppm and 13.12 ppm were assigned to H9 and H13 by the observed ROESY correlations from H8
to H9, and H13 to H14, respectively.
From a computational analysis, the lowest energy conformation of aleutianamine was
optimized by the density functional theory (DFT) calculation at B3LYP/6-311++G(3d,3p) level
with the PCM (Polarizable Continuum solvation Model) using dielectric constant representing
DMSO. The calculation verified the half-chair conformation of the six-membered ring constructed
by C1 through C6 and all other reasonable molecular geometries. As a computed result, all of the
calculated distances between non-exchangeable protons were under the classified ROESY distance
constraint ranges which were deduced from the signal integration values (Table S2). Highly
noteworthy, the experimental values of the signal intensities were exponentially regressed with the
computed distances.
The final structure was considered to be rigid and conducive for a reliable geometry
optimization at acceptable computational cost due to the many ring constraints. The absolute
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configuration of aleutianamine was then determined by overlaying the computed ECD curves with
the experimental ECD spectra. Based on the elucidated relative configuration using NMR, the
conformational analysis was conducted using the Amber force field method followed by the PM6
semi-empirical optimization in tandem to acquire the pre-optimized geometries. It resulted in only
one local minimal in addition to the global minimal energy conformation, which were produced
by the half-chair conformational interconversion on the six-membered ring formed by C15 through
C20. Acquired from a DFT calculation, the relative total energy of these two low energy
conformers was about 5.3 kJ/mol. Each DFT optimized structure was then used for excited state
calculations by using the TD-DFT method. The calculated excitation energies and rotatory
strengths of each conformer were weighted to the Boltzmann average, and then introduced to the
Gaussian function to generate the simulated ECD curves. From the comparison (Fig. 9), the
absolute configuration of aleutianamine was unambiguously assigned as 3R, 5R, 8S.

Figure 8. Key HMBC, COSY, and ROESY correlations

Figure 7. Structure of aleutianamine
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Figure 9. Overlaid experimental ECD spectra with the computed ECD curves at B3LYP/6-31G(d,p) level.

Differentiation of the Br-substituted sp2 13C-NMR signals from those non Br-substituted
sp2 carbons, based solely on

13

C or 1H chemical shifts is unreliable because of the similarity

chemical shift86. However, in optical cases, Br-substituted carbon can be identified by 1H and 13C
NMR chemical shift calculations using gauge the independent atomic orbital (GIAO)87-89method
at the PCM/mPW1PW91/6-311+G(d,p) level of theory89 for DP4+calculations90. two possible
regioisomers of aleutianamine having the bromo substituent at C-1 and C-2 a regioisomer with
swapped positions of NH and S were employed for DFT and DP4+ calculations. The calculated
chemical shifts of aleutianamine-1 (3R, 5R, 8S), aleutianamine-1′ (3R, 5R, 8S), and aleutianamine1′′ (3R, 5R, 8R) were compared to the experimental 1H and

13

C NMR chemical shifts via the

corrected mean absolute error (CMAE) as well as DP4+ probability chemical shift analysis (Fig.
10). The CMAE results showed that aleutianamine-1 (3R, 5R, 8S) was the most probable isomer
(Fig. 10). These results were corroborated by the DP4+ statistical analysis, which predicted
aleutianamine-1 (3R, 5R, 8S) with a probability of 100%. It is worth noting, however; that DP4+
predicted aleutianamine-1′ (3R, 5R, 8S) based on the 1H NMR data only, aleutianamine-1 (3R, 5R,
8S) based on the 13C NMR data only, and aleutianamine-1 (3R, 5R, 8S) based on 1H and 13C NMR
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data. Collectively, the excellent agreement between NMR spectroscopic and computational data
strongly supported the (3R, 5R, 8S) absolute configuration of aleutianamine.

Proton
Carbon
Both

Aleutianamine-1
DP4+
CMAE
0.01%
1.08
100.00%
2.58
100.00%
3.66

TAD
14.01
46.45
60.46

Proton
Carbon
Both

Aleutianamine-1′
DP4+
CMAE
99.99%
0.76
0.00%
3.26
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9.84
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DP4+
CMAE
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11.12
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Figure 10. Total absolute deviation (TAD), mean absolute error (MAE), and DP4+ probability analyses
(sarotti-nmr.weebly.com) for 1 and three of its diastereomers (Gibbs free energies at the
PCM/mPW1PW91/6-311+G(d,p) level were used for the analysis).

The unique aleutianamine ring system demonstrated solid tumor selectivity in the
differential cytotoxicity zone assay used for discovery of new anticancer leads.25 Selectivity of cell
killing was noted for murine colon cancer 38, human breast cancer MCF-7, human prostate cancer
LNCaP and human PCPANC-1 compared to both murine and human leukemia cells. This breadth
of selectivity is unusual for active compounds which usually demonstrate selectivity to only one
of the cell types tested against. The IC50 value for aleutianamine tested against human HCT-116
colon cancer cells was 0.1 uM indicating reasonably potency. Clonogenic studies were carried out
using HCT-116 cells to define the concentration-survival relationship as a function of exposure
time.26 The endpoint used, tS10 (10% survival of clonogenic cells for exposure time t) provides
information essential for future preclinical therapeutic studies. These clonogenic studies yielded a
2S10

value of >5 uM; a 24S10 value of 0.75 uM; and, a 168S10 value of 0.1 uM. The clonogenic data

indicated that, depending upon the pharmacokinetics and maximum tolerated dose of

43

aleutianamine, a chronic treatment might be expected to be efficacious. The principal structural
feature of discorhabdin is the core of a planar iminoquinone moiety which can intercalate into
DNA and cleave the DNA double helix or inhibit the action of topoisomerase II. The
makaluvamines except makaluvamine B are topoisomerase II inhibitors acting via cleavable
complex formation, or via the direct induction of DNA double-strand breaks. Makaluvamine A
and C are reported to decrease tumor size in a solid human tumor model. However, discorhabdins
A and C exhibited no inhibition of topoisomerase II in contrast of their significant cytotoxicity
Table 3. Anti-cancer cells disk diffusion assay result.

PANC-1

MDA

U251N

(Glioblastoma
LNCaP

cell lines)

MCF-7

H-125

DMSO

H-116

(mg/ml)

(colon cancer()
Colon 38

Leukemia cells

Conc.
Compound

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

>1000

>1000

Ecdysone

2

0

0

0

Aleutianamine

2

950

>1000

>1000

"

0.5

700

>1000

950

>1000

>1000

"

0.125

500

900

600

900

>1000

1000

850

800

>1000

"

0.03125

250

450

250

400

600

500

700

500

650

Discor A

2

1000

750

>1000

"

0.5

300

800

900

950

800

300

1000

450

"

0.125

250

700

500

750

600

500

300

500

150

"

0.03125

400

350

250

200

300

100

Karlotoxin 2

2

100

200

400

150

200

200

100

150

100

200

200
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with the same core inimoquinone skeleton suggesting a different mechanism.
Discorhabdins A and C demonstrated the highest cytotoxicities against several tumor cell lines.
Based on the data we have, aleutianamine showed higher cytotoxicity than discorhabdin A towards
cancer cell lines and demonstrated selective inhibition to PCcell lines making its further
development as anticancer drug.
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Scheme 1. Biosynthetic Conversion: Discorhabdin A to Discorhabdin B; and A or B to Aleutianamone. Reduction of Aleutianamone leads to
Aleutianamol(s) en route to Aleutianamine.
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Figure 11. 1H NMR spectrum of aleutianamine in DMSO-d6
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Figure 12. 13C NMR spectrum of aleutianamine in MeOD-d4

C-1
C-6
C-11

C-19
C-10

C-14
C-20
C-12
C-15

C-2

C-8
C-17
C-3
C-5

C-7

C-4

C-16

C-21

47

Figure 13. 13C NMR spectrum of aleutianamine in DMSO-d6
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Figure 14. DEPT 135 NMR spectrum of aleutianamine in MeOD-d4
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Figure 15. 2D 1H-13C HSQC NMR spectrum of aleutianamine in DMSO-d6

49

Figure 16. 2D 1H-13C HMBC NMR spectrum of aleutianamine in DMSO-d6
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Figure 17. 2D 1H-1H COSY NMR spectrum of aleutianamine in DMSO-d6
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Figure 18. 2D 1H-1H ROESY NMR spectrum of aleutianamine in DMSO-d6
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Figure 19. 2D 1H-15N HMBC NMR spectrum of aleutianamine in DMSO-d6
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Figure 20. FT-MS spectrum of aleutianamine
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CHAPTER TWO
THE MICROBIOME OF AMERICAN SYCAMORE PRODUCES RAPAMYCIN AS PART
OF A UNIQUE SYMBIOTIC PLANT-ENDOPHYTE RELATIONSHIP

Bacillus.
amyloliquefaciens
Platanus. occidentalis

MS image of
rapamycin

Introduction
Plant-microbiome association studies have revealed that symbiotic microorganisms are
known to chemically protect the host but at the same time overgrowth of the endophyte also can
cause harm to the plant. The role of natural products in microbiome-plant associations and the
overall success of the host remains largely unexplored. Here, we show American sycamore
(Platanus. occidentalis L.) tissue contains rapamycin and iturin lipopeptides and that these
secondary metabolites are produced by a Bacillus. amyloliquefaciens subsp. plantarum strain
isolated from the plant microbiome by LC-MS, MALDI-IMS, NMR. Rapamycin and plantazolicin
production were limited to within the growing colony while lipopeptides were excreted. It has been
reported that when the Target of Rapamycin (TOR) is inhibited in plants treated with rapamycin,
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it will promote autophagy of the cells and differentiation of xylem tracheary elements as well as
extend the life-expectancy of the plant36. These results revealed that rapamycin generated by B.
amyloliquefaciens appears to play a key role in the development of vascular tissue to transport
water in this species of tree, promote autophagy of autumn leaves thus recovering nutrients and
contribute to sycamore unique longevity. We also exhibited that American sycamore produced
platanosides showed a seasonal and plant organ specific difference in concentration and dose
dependent inhibition to B. amyloliquefaciens, suggesting plant host regulation of B.
amyloliquefaciens subsp. plantarum. The metabolites from endophytes and hosts mediate the
interaction to realize the success of this species.
Plant-microbiome symbiosis represents some of the oldest and most well established
symbiotic relationships on our planet. Symbiotic microorganisms are well established promoters
of plant health through the generation of natural pesticides for the plant in addition to nitrogen
fixation34-35. At the same time overgrowth of endophytes can cause harm to the plant33. Plants
generate structurally diverse metabolites with important functions in influencing interactions
between both members of their external environment in addition to their microbiome. These
antimicrobial compounds are often stored in specialized organs and tissues91. An understanding of
the chemical function and the overall success of the host remains largely unexplored and
challenging due to trace levels below detection, or limitations in chemoinformatics tools91.
The family Platanaceae is among the living fossils of our planet and an old family of
angiosperms extending back to the Early Cretaceous92-94. The genus Platanus represents the only
living member of the family and are large perennial trees growing up to 50 m high and 4 m in
diameter95. The genus Plantanus is found throughout the world and the ‘Tree of Hippocrates’ is a
member of this genus group. Platanoside isolated from the sycamore leaves has shown potent
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antibiotic activity against Methicillin-resistant Staphylococcus aureus (MRSA)95-96 and is
currently under development as a new class of antibiotics.
B. amyloliquefaciens subsp. plantarum strains have been isolated from soil as well as the
inner tissue of numerous plant shoot and root anatomical structures across many species97-100. It
is mainly used in agriculture, aquaculture and hydroponics to fight root pathengens101 as well as
improve tolerance to salt stress102. To date, elucidated benefits of B. amyloliquefaciens to the plant
host include pathogenic defense, seedling emergence and overall growth promotion, gibberellin
production, plant endogenous hormone regulation, and stimulation of plant host immunity, among
others97-99, 103. A comparative analysis of the genome of B. amyloliquefaciens subsp. plantarum
FZB42 to the model organism B. subtilis showed it contains an unusual proclivity for producing
secondary metabolites97. B. amyloliquefaciens recently followed B. subtilis in being divided into
subspecies, which distinguishes between strains that cluster with B. amyloliquefaciens DSM 7 and
those that cluster with plant-associated, growth-promoting strains104. Importantly, the plantassociated types, now named B. amyloliquefaciens subsp. plantarum with an addendum of the
specific isolated strain, contain more than twice the genetic capacity for non-ribosomal secondary
metabolite biosynthesis97, 104. Iturin and fengycins are B. amyloliquefaciens common metabolites
and possess well established anti-fungal activity against many known plant pathogens.
Rapamycin is a macrocyclic lactone first and only reported from a soil sample of Easter
Island

providing the rapamycin producing bacterium Streptomyces hygroscopicus (S.

hygroscopicus)105. Rapamycin has found clinical utility for the treatment of organ rejection
following renal transplant surgery and the amelioration of some side effects associated with
alternative treatments106. Rapamycin has been shown to have antifungal107 and antitumor
activity108 and has also been reported to extend lifespan in both vertebrate and invertebrates,
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including yeast, nematodes fruitflies and mice109-112. An array of studies have shown that
rapamycin can induce cell autophagy, arrest plant growth, differentiate xylem tracheary elements
as well as extend the life-expectancy of the plant 36. Studies in yeast into the mechanism of action
of rapamycin led to the discovery of TOR proteins, serine/threonine kinases that couple cellular
inputs to spatial and temporal cell growth in eukaryotes113-114. These proteins are highly conserved
among all eukaryotes and much of the TOR signaling pathway evolved before the Last Eukaryotic
Common Ancestor114-116. In mammals, TORs form two distinct complexes, Target of Rapamycin
Complex (TORC) 1 and 2, and rapamycin only inhibits TORC1. Plant genomes encode orthologs
of known components of TORC1 and numerous studies have shown the presence of TORC1 in
plants, but not TORC2117. Arabidopsis thaliana was originally reported as insensitive to rapamycin,
but later studies in showed rapamycin inhibits glucose-mediated root and leaf growth, and studies
in maize (Zea mays L.) also displayed plant sensitivity to rapamycin118-119. In photosynthetic plants,
TOR signaling regulates translation, transcription, autophagy, and primary and secondary
metabolism and is integral to photosynthesis, embryogenesis, meristem activation and flowering,
and other aspects of plant life120.
Here we present solid evidence that the plant microbiome B. amyloliquefaciens cultured
from American sycamore produce rapamycin as shown by HR-LCMS, NMR, mass imaging (MI)
and molecular ion networking (MoIN). A metabolomics analysis using MoIN of sycamore tissues
revealed that the vegetative state of B. amyloliquefaciens inhabits the xylem but not the healthy
leaves. Published results show that inhibiting TOR in plants will promote autophagy and
differentiation of xylem36, indicating that rapamycin from the microbiome helps to create vascular
tissue by promoting differentiation of xylem and in the autumn assist in energy recover from leaves
by promoting autophagy. Thus rapamycin appears to play a significant role in the transport of
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water to the top of these tall trees as well as recovery of nutrients from leaves before they are shed
in the autumn. We also found the antibiotic platanoside concentrations of summer leaves showed
dose-dependent inhibition to the growth of B. amyloliquefaciens and the metagenomics results
support that B. amyloliquefaciens resides in the xylem but not the summer leaves. Coupled with
the reported physiological function of TOR, our experimental results demonstrate that during the
summer the high yield of platanoside in the sycamore leaves prevents B. amyloliquefaciens from
migrating into the leaves and are restricted to the vascular tissues of the trunk and branches. During
autumn the antibiotic concentration to the leaves drops to levels that can be tolerated by the
Bacillus sp. The spores of the bacterium can then germinate in the leaves where it induces
autophagy of leaf cells prior to the leaves falling from the tree. Thus the tree recovers as many key
nutrients from the leaf as possible before they fall from the tree in the autumn.
Experiments and methods
Endophytes isolation and metabolites extract. American sycamore stem material was surface
sterilized using 80% ethanol for 4 minutes under bio-hood under sterile conditions. Outer and
inner bark tissue were peeled off and exposed inner stem were placed directly on CS20 malt agar
plates which were incubated at 36 °C for 48 hours. Sub-cultured plates were used to make (10) 5
mL liquid cultures under sterile conditions. 5 mL liquid cultures were shaken at 160 RPM and
36 °C for 24 hours. Glycerol stocks were made by pipetting 600 µL of liquid culture and 400 µL
of 80% glycerol into Eppendorf tubes. Tubes were placed in -80 °C freezer for storage.
Analysis of rapamycin from metabolites of endophytes: the metabolites of endophytes were
extracted with hexane, dicholoromethane (DCM), and methanol successively. Extracts were
evaporated and solubilized in 100% MeOH to 1 mg/ml. The injected samples were
chromatographically separated using an Agilent analytical UHPLC (Santa Clara, CA) using a 100
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X 4.6 mm Kinetex 1.7 µM, C8, chromatography column (Phenomenex Torrance, CA), 1 mL/min
flow rate, mobile phase A 99.9% water (VWR, LC-MS grade), 0.1% formic acid (VWR); mobile
phase B 99.9% acetonitrile (VWR, LC-MS grade), 0.1% formic acid (VWR); with the following
gradient: 0-1 min 5% B, 1-15 min 100% B, 15-25 min, 100% B, 26-30 min, 5% B. The DCM
fraction contained signals that correlated with the sodium adduct [M+Na]+ at m/z 936.6,
ammonium ion [M+NH4] + at m/z 931.6 and, and potassium ion [M+K]+ at m/z 952.6 at the same
retention time as a standard rapamycin injection. The DCM fraction also contained signals that
correlated with the sodium adduct [M+Na]+ at m/z 1079.6 and proton ion [M+H]+ at m/z 1057.6 at
the same retention time as iturin A3 injection.
CS20 Media
Table 3 shows the components of the media that was used for all bacterial secondary metabolite
production. This media was originally developed for the culturing of fastidious organisms and
contains many components not usual in media used for the culturing of endophytic organisms.121
The commonly used yeast LB medium was used to culture Bacillus endophyte, but although
lipopeptide production was noted by LC-MS by the presence of singly and doubly charged ions,
no rapamycin was produced using this media.
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Table 3: CS20 Media.

Distilled H2O

1L

Soy peptone

2.0 g

Bacto tryptone

2.0 g

(NH4)2HPO4

0.85 g

Hemin Cl (0.1%)

15.0 mL

KH2PO4

1.0 g

MgSO4 .7H2O

0.4 g

L-glutamine

6.0 g

Dextrose

1.0 g

Starch, potato soluble 2.0 g
L-histidine

1.0 g

Phenol red (0.2%)

5.0 mL

Agar

12 g

pH

6.6-6.7
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Isolation and purification of rapamycin from sycamore tissue. The air-dried and powered
American sycamore leaves (17 kg) were extracted with 190 proof ethanol at room temperature.
The extract was concentrated in vacuo to yield a residue (860 g), the residue was washed by hexane,
dichloromethane and methanol successively. The dichloromethane residue was chromatographed
on silica gel column eluted with a gradient hexane/ethyl acetate. Fraction rich rapamycin checked
by LC-MS was further purified by semi-preparative HPLC (acetonitrile/water) to give rapamycin
less than 0.4mg (Fig.21). The 1H-NMR and HSQC spectra were recorded on Bruker 850 MHz
NMR spectrometer (Fig. 22).
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Figure 21. Isolation scheme of rapamycin from sycamore leaves.
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Figure 22. Rapamycin isolation from Platanus occidentalis tissue by LC-MS (A) Precursor [M+NH4]+ ion
at m/z 931.5922 (2.93 ppm) was detected from an extract of secondary growth tissue along with ions
representing neutral losses of methanol and water at m/z 882.5391 (2.78 ppm) and m/z 864.5289 (3.19 ppm)
(B) H-NMR of purified rapamycin (red) and standard rapamycin (green). (C) Overlapped HSQC of isolated
rapamycin (red) from the sycamore leaves and standard rapamycin(blue)

Characterization of rapamycin producing endophyte Because the nucleotide sequences found
in 16S rRNAs vary in an orderly fashion throughout the phylogenetic tree, these sequences have
been useful for the study of molecular evolution122. Now the amount of 16S rRNA sequence in
NCBI database is so many that 16S rRNA sequence for identifying species become more and more
sensitive. One pair of primers is capable of amplifying nearly full-length 16S ribosomal DNA
(rDNA) from many bacterial genera; the additional primers are useful for various exceptional
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sequences [2]. If researchers want to identify a bacteria strain in the level of genus, the general
primer for amplifying 16S rDNA sequence is enough, and the primers are 1429R/27F123 (149R:
GGTTACCTTGTTACGACTT 27F: AGAGTTTGATCCTGGCTCAG) for 1500 bp which design
in the conserved region of 16s rDNA sequence. If researchers want to further identify a bacteria
strain in the level of species, the specific primer should be designed in the variable region of 16s
rDNA sequence.
MALDI-IMS analysis. Seven CS20 agar plates were poured with days 1-5 poured with 10 mL of
agar and plates for days 6 and 7 poured with 15 mL of agar. 5 µL of B. amyloliquefaciens.
containing glycerol stock was placed in the center of each of these plates and placed in an incubator
at 36˚C. One plate was removed every 24 hours and colonies were excised from the agar plate and
placed on a Bruker MTP 384 steel plate. After a picture of the colony was taken for later overlay
using imaging software, alpha-cyano-4-hydroxycinnamic acid matrix was shaken on top of the
colony using a 20 µm sieve for even distribution of the matrix. The steel plate was then placed in
an incubator at 36˚ C for four hours. Afterwards, the plate was placed in a desiccator. The
desiccator was then placed under vacuum for 5 minutes and then sealed and the plate was left
inside for an additional 25 minutes. The plate was then removed and placed into a Bruker Autoflex
II mass spectrometer equipped with the Compass 1.1 software suite (consisting of FlexImaging
3.0, FlexControl 2.4, and FlexAnalysis 2.4). The samples were analyzed in linear positive mode
with 200 µm intervals. The spectra were collected in the m/z 700-1600 range at a 200 Hz laser
frequency. After data acquisition, the data was analyzed using FlexImaging software.
Diffusion experiment. Bacillus is cultured in CS20 specific medium, Wide ranges of percent
glycosides (0.5%-0.1%) have been tested, where each concentration is mixed with about 20 mL
media to overcome the poor diffusion properties of theses metabolites, autoclaved (the glycosides
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show recognized stability at the autoclaved temperature), cool down, and then organism followed
by incubation for about 48 hrs at 37 ºC.
Purification and analyzing the yield of platanoside from P. occidentalis
Air-dried summer leaves (3.5 kg) of P. occidentalis different sizes were macerated at room
temperature with ethanol, yielding 465 g of extract residue. The ethanolic extract (465 g) was
washed with dichloromethane and water. The residue was subjected to reverse phase silica gel
vacuum-liquid chromatography (VLC), yielding a fraction 67E with MeOH-Water (3:1) (17 g)
which was chromatographed on a silica gel column, eluting with a hexane- ethyl acetate gradient
system (5:1, 3:1, 2:1, 1:1, 0:1) to afford pure platanosides (2.5 g, Fig. 23) identified by NMR and
HRESIMS (Fig. 24). 200 gram of air-dried and powered P. occidentalis summer and autumn
leaves as well as the xylem and cambium were extracted with hexcane, DCM and methanol
separately. Extracts were evaporated. Then the methanol extracts were analyzed with an Agilent
1100 HPLC utilizing a Phenomenex Luna C18 column (4.6 x 150 mm, 5 µm, 100 Å) in-line with
a Bruker microTOF ESI mass spectrometer operating in positive ion mode.
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Figure 23. Isolation scheme of platanoside from American sycamore

(A)

Figure 24. 1H-NMR of platanoside. The overlayed LC/MS chromatogram of isolated platanoside and the
standard.
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Table 4. Different parts of sycamore tree used to analyze the yield of platanoside (The experiment was
repeaated for 2 times)

P. occidentalis tissue type

Hexanes ext.(g)

Chloroform ext. (g)

Methanol ext.(g)

Healthy summer leaves (200g)

1.3

4.5

36

Healthy autumn leaves (200g)

2.2

4.9

4

Xylem (200g)

0.54

0.21

3.6
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PLATANOSIDE

ITURIN A3

Summer leaves

0.5%

Below detection

Autumn leaves

0.15%

Below detection

Summer xylem

0.09%

+

Figure 25. Calibration curve and the yield of platanoside.

In vitro Inhibition of Bacillus Assay. Bacillus is cultured in CS20 specific medium, Wide ranges
of percent glycosides (0.5%-0.1%) have been tested, where each concentration is mixed with about
20 mL media to overcome the poor diffusion properties of theses metabolites, autoclaved (the
glycosides show recognized stability at the autoclaved temperature), cool down, and then apply
the organism followed by incubation for about 48 hrs at 37 ºC.
Results and discussion.
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Bacillus amyloliquefaciens isolation from plant tissues and rapamycin expression.
The first indication that rapamycin was present in American sycamore tissue was from an
ESI LC-MS injection from a methanol extraction of secondary-growth containing ground
American sycamore tissue (Fig. 22). A signal matching the ammonium adduct at m/z 931.5922
Da (2.93 ppm) was seen, along with ions representing a neutral loss of methanol at m/z 882.5391
(3.33 ppm) and a neutral loss of methanol and water at m/z 864.5289 (3.82 ppm) (Fig. 22). An
injection of a rapamycin standard from S. hygroscopicus under the same conditions yielded the
same ammonium adduct at m/z 931.5907 (1.32 ppm) at approximately the same retention time
with ions representing neutral losses of methanol at m/z 882.5391 (1.63 ppm) and methanol and
water at m/z 864.5279 (2.66 ppm) (Fig. 22). A large-scale study of American sycamore was
initiated to further confirm the presence of rapamycin. Seventeen kilograms of whole leaf tissue
of American Sycamore tissue including the leaf petiole was extracted to yield a total of 0.8 mg of
rapamycin (Fig. 21).
B. amyloliquefaciens subsp. plantarum was isolated from secondary growth-containing
American sycamore tissue for study of its secondary metabolism. BLAST results put the American
sycamore isolated species closely related to B. amyloliquefaciens subsp. plantarum AS43.3 and B.
amyloliquefaciens subsp. plantarum TrigoCor 1448, which have been isolated from the wheat
rhizosphere and wheat spikes, respectively124. Different media were used to study B.
amyloliquefaciens subsp. plantarum secondary metabolism. Three of them, Landy’s, LB and malt
have a history of use in Bacillus fermentation, while CS20 and CHARD2 do not125-127. CS20 and
CHARD2 were both created for the culturing of fastidious organisms and both contain
supplemental amino acids, but CS20 combines this with plant-based carbon sources. Throughout
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all experiments with the American sycamore-sourced B. amyloliquefaciens subsp. plantarum
species, it was only CS20 that allowed for the detection of rapamycin.
MALDI-IMS was used to study the spatial, two-dimensional aspects of B.
amyloliquefaciens subsp. plantarum secondary metabolite production. Ionic species matching
rapamycin, plantazolicin, and known Bacillus lipopeptides were detected (Fig. 26). The signals
matching rapamycin and plantazolicin were consistently seen within the bounds of the irregularshaped colony, while signals matching Bacillus lipopeptides fengycins and iturins were mostly
detected outside (Fig. 27), indicating they had been excreted during production (Fig. 27).
Fengycins and iturins both possess proven anti-fungal activity against many known plant
pathogens. More recent studies have pointed to a role for each in the induced systemic resistance
response in particular species103. Fengycins have elicited plant phenolic production in potato tuber
cells and iturins upregulated defense genes in chili pepper including chitinase and peroxidase128129

. Plantazolicin has recently been shown to be a highly selective in its antibacterial activity,

discriminating even between other members of Bacillus and showing particular activity against
Bacillus anthracis130. The roles rapamycin could have in influencing plant behavior are hard to
predict, simply because of the pervasive role TOR signaling in so many aspects of plant life. In A.
thaliana, rapamycin inhibits glucose-induced root, root hair and leaf growth. Rapamycin has
shown the ability to inhibit glucose-activated DNA synthesis in isolated nuclei from the embryonic
axes of maize seedlings as well as in in vitro maize cell suspension cultures which correlated with
an overall inhibition of mitosis and ribosome biogenesis119. Isotope ratio analysis was applied to
show the difference between the origin of standard and isolated rapamycin from sycamore. The
result demonstrated that there is clearly an additional concentration of one or more M+3 ions (13C,
2D, or 15N) in rapamycin standard but not in rapamycin isolated in sycamore (Fig 28), revealing
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the two metabolites do not possess the same isotopic composition. This difference may be caused
by enzyme kinetics between the Bacillus and Streptomyces product, or different concentration of
heavy isotopes in the different media.

Figure 26. MALDI-IMS of Bacillus spp. colonies in CS20 medium. Five colonies of endophytic Bacillus
sp. were plated with liquid culture and incubated at 37° C on specialized media originally developed for
fastidious microbes and successively removed from incubation in 24 time point intervals. (I) MALDI-IMS
shows signals correlating with [M+H]+ ion of rapamycin at m/z 914.6, [M-H2O]+ ion of rapamycin at m/z
896.7, [M+K]+ ion of rapamycin at m/z 952.3. The ionization efficiency of the dehydration product and
potassium adduct corresponded with an increase in incubation time and dehydration of the solid agar.
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Figure 27. MALDI-IMS of B. amyloliquefaciens. colonies in CS20 medium. (I) MALDI-IMS shows
signals correlating with [M+H]+ ion of rapamycin at m/z 914.6, [M-H2O+H]+ ion of rapamycin at m/z 896.6,
[M+K]+ ion of rapamycin at m/z 952.5, [M+K]+ ion of iturin A2 at m/z 1081.03, [M+K]+ ion of fengycin at
m/z 1503.4, [M+H]+ ion of plantazolicin at m/z 1336.5. overlaid MALDI-IMS of fengycin (yellow) and
plantazolicin (orange) as well as iturin (yellow) and rapamycin (red), clear showing that rapamycin and
plantazolicin were within the bounds of the irregular-shaped colony, while fengycins and iturins were
mostly excreted outside.
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Figure 28. Rapamycin was present in American sycamore tissue from an ESI LC-MS injection from a
methanol extraction of secondary-growth. A: A signal matching the ammonium adduct at m/z 931.5922
Da (2.93 ppm) was seen, along with ions representing a neutral loss of methanol at m/z 882.5391 (3.33 ppm)
and a neutral loss of methanol and water at m/z 864.5289 (3.82 ppm). B,: An injection of a rapamycin
standard from S. hygroscopicus under the same conditions yielded the same ammonium adduct at m/z
931.5907 (1.32 ppm) at approximately the same retention time with ions representing neutral losses of
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methanol at m/z 882.5391 (1.63 ppm) and methanol and water at m/z 864.5279 (2.66 ppm). An additional
concentration of one or more M+4 ions (13C, 2D, or 15N) in rapamycin standard but not in rapamycin
isolated in sycamore.

Molecular Ion Networking (MoIN) studies to show the distribution of B.
amyloliquefaciens.
Networking enables to visualize observed molecules as familial groupings in which commonalities
within the MS fragmentation data are assessed via vector correlations and displayed as an MS/MS
network. The visualization of networks by using Cytoscape enable the direct observation of
similarities as well as differences between two or more samples in which similar entities within
the network are clustered together while disparate or unique entities are grouped separately76.
Endophyte populations in nature are always interacting with their host. The MS/MS data were
collected from the injection of the methanol extract of B. amyloliquefaciens, American sycamore
summer leaves and xylem. Vector similarities are calculated for every possible pair of spectra with
a minimum of six matching fragment ions (i.e., peaks) with similarity determined by using a
modified cosine calculation that takes into account the relative intensities of the fragment ions as
well as the precursor m/z difference between the paired spectra. Edges between spectra are retained
only if in the top K for both paired spectra and the vector similarity score, represented as a cosine
value, of the match is greater than the user-defined threshold. Cosine threshold values are set 0.7
whereby a cosine value of 1.0 indicates identical spectra. These data were then imported to
Cytoscape. The organized landscape of the molecular networking produced by Cytoscape (Fig. 29)
shows that the platanoside as well as the analogs are localized in American sycamore summer
leaves and xylem, while rapamycin compounds are present in B. amyloliquefaciens, which have
been observed before by MALDI imaging. Interestingly, networking showed the metabolites of B.
amyloliquefaciens are identical or related to xylem extract, but have no common molecules with
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American summer leaves, indicating that B. amyloliquefaciens inhabiting in xylem instead of
leaves.

Figure 29. Molecular networks obtained from B. amyloliquefaciens, American sycamore leaves and xylem.
It should be noted that the metabolites of B. amyloliquefaciens are overlapped or related to the crude extract
of xylem but has nothing to do with the crude extract of leaves. This can be attributed to the different
concentration of platanoside which can inhibit the growth of B. amyloliquefaciens in different parts of the
tree.

Platanoside exhibited a seasonal and plant organ specific difference in concentration and
dose dependent inhibition of B. amyloliquefaciens
American sycamore produced antibacterial platanosides, also inhibit the growth of B.
amyloliquefaciens subsp. plantarum. Inhibition of B. amyloliquefaciens by platanoside occurs in
a dose-dependent manor with 0.5% platanoside concentration exhibiting complete inhibition of
the endophytic species and 0.1% showing no clear inhibition (Fig. 31). There are distinct
differences seen in the concentration of plant host produced antimicrobial platanosides by plant
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organ and by season (Fig. 30). Leaf material consistently contained more platanosides than stem
material, and autumn leaves contained less than summer leaves. This suggests American sycamore
exhibiting a seasonal and plant organ specific difference in concentration of platanoside regulates
B. amyloliquefaciens endophyte and that this regulation varies based on plant-host needs.

Figure 30. Heatmap of platanoside concentration in different part of the P. occidentalis tree, 0.5% in
summer leaves, 0.15% in autumn leaves, 0.009% in xylem and 0.004% in cambium.
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Figure 31. Platanoside inhibit the growth of bacillus when treated at the concentration of 0.5% and 0.4%.

Convergent evolution pathway for rapamycin in B. amyloliquefaciens
Bacillus sp. possess the biosynthetic genes responsible for the production of a diversity of
secondary metabolites including bioactive peptides, alkaloids and polyketides using modularly
organized nonribosomal peptide synthetases (NRPSs) and polyketide synthases (PKS) (Fig. 32)13.
In addition, this group of bacteria are capable of generating unusual hybrid PKS and NRPSs that
are of mixed biosynthetic origin like rapamycin. Thus the potential for a convergent pathway to
rapamycin by B. amyloliquefaciens is indeed plausible131. It is noteworthy that a wide variety
different media were used to study B. amyloliquefaciens subsp. plantarum secondary metabolism,
however, only CS20 media was successful in the generation of rapamycin. CS20 is a highly rich
medium designed for the culture of bacteria from plant microbiomes potentially leading to the
changes of transcripts as well as providing key biosynthetic precursors132. Based gene sequence
analysis result (Fig. 33), there are unassigned type 3 PKS and "PKS-like" which size is big enough
to build rapamycin. We assume it is the Non-homologous Isofunctional Enzymes (NISE) which
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share no sequence similarity with each other catalyzing the same reaction that cause the different
isotope ratio of Bacillus and Streptmyces rapamycin product133-134.

Figure 32. Primary second metabolites of B. amyloliquefaciens

Figure 33. antiSMASH Analysis of the gene sequence of B. amyloliquefaciens.
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CHAPTER THREE
ASSIGNMENT OF THE ABSOLUTE CONFIGURATION OF HEPATOPROTECTIVE
HIGHLY OXYGENATED TRITERPENOIDS AND DIBENZOCYCLOOCTADIENE
LIGNANS USING X-RAY, ECD, NMR J-BASED CONFIGURATIONAL ANALYSIS AND
HSQC OVERLAY EXPERIMENTS

Published in Molecules 2017, 22, 65-69; BBA - General Subjects 2017, 1861, 3089–3095; Org.
Lett. 2018, 20, 5559−5563, Accepted in Nat. Prod. Commun.
Introduction:
The chronic liver disease caused by xenobiotics and viral infection will eventually lead to
liver cancer; the second most common cancer in the world. In 2018, WHO reported that around
788,000 people die from primary liver cancer every year. It is also reported that from 1999 to 2015,
deaths from liver cancer in the US increased by 60% while deaths from other cancers decreased
by 26%. More than 60% of these deaths are caused by the long-term consequence of chronic
hepatitis B (HBV) and C (HCV) infections. Exposure to certain chemicals, cirrhosis of the liver,
and diabetes are additional causes for liver cancer. In 2015, more than 325 million people
worldwide were living with HBV and HCV infection causing 1.34 million deaths. Levels of both
hepatitis testing and treatment are still extremely low in most regions of the world reaching only
1 or 2 out of every 10 people in need.135 Traditional medicines and small molecule drugs still play
a vital role in controlling liver disease.
An effective approach to chronic liver disease control is chemoprevention, which can help
improve abnormal liver function and inhibit hepatitis replication and may cause fewer side effects.
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Several antiviral nucleoside/nucleotide analogues including lamivudine, adefovir, dipivoxil, and
entecavir have been successfully used to treat chronic hepatitis B (HBV) or chronic hepatitis C
(HCV) infections. However, the therapeutic efficacy of these drugs is still limited and side effects
including serious nephrotoxicity and mitochondrial toxicity are rather frequent. The effectiveness
of nucleoside/nucleotide analogues is also limited because drug resistance develops, including
mutations that occur in the YMDD motif of HBV DNA polymerase, particularly for lamivudine.136
Dibenzocyclooctadiene lignans and triterpenoids are the primary hepatoprotective active
ingredients of Schisandra chinensis and Kadsura longipedunculata which are known as “liver
tonic” in Asian Herbal Medicine for chronic liver disease and poor liver function. Interestingly,
two liver therapies have been designed using schisandrin C, a dibenzocyclooctadiene lignin
isolated from S. chinensis and K. longipedunculata, as a model. These include diphenyl dimethyl
bicarboxylate (DDB)137 and bicyclol.138 Clinical trials found that bicyclol is effective in improving
abnormal liver function, inhibiting the replication of HBV in chronic hepatitis B patients as well
as inducing differentiation of human hepatocarcinoma cells (HepG2 and Bel-7402 cells) without
side effects being reported.139 These results implicate the possibility of dibenzocyclooctadiene
lignans as promising chemopreventive agents active in the control of liver carcinogenesis. Their
2D structures and relative configurations have been successfully elucidated by NMR spectroscopic
methods. Assignment of their absolute configurations is challenging especially for the schiartanetype nortriterpenoids due to the presence of 12 non-contiguous stereogenic centers as well as
conformationally flexible side chains. Single crystal X-ray diffraction remains the gold standard
in the structure elucidation of novel and known molecules. However, a crystal that diffracts well
is not always easily obtained, especially for the small quantities of natural products. 77 For the
assignment of the relative configuration of non-crystallized , NMR-based techniques including
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NOE and J-based configuration analysis (JBCA) in combination with molecular and quantum
mechanics calculations including DP480 as well as DP4+ calculations140 were applied.141 For the
absolute configuration, electric circular dichroism (ECD) methods, calculated ECD as well as
mosher reaction have often been used.

,

Figure 34. the structures of compounds 1-7.
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Material and methods.
General procedures.
Optical rotations were measured on a JASCO P-2000 polarimeter and UV spectra with a
JASCO V-650 spectrophotometer. ECD spectra were measured on a JASCO J-815 spectrometer.
The 1H and

13

C NMR spectra were recorded on INOVA-500 and BRUKER AV500-III

spectrometers. HETLOC and HSQC with decoupling were measured on a Bruker 850 MHz NMR
spectrometer. The standard Bruker pulse sequences were used for each 2D measurement.
HRESIMS data were acquired using an Agilent 6520 Accurate-Mass Q-Tof LC/MS mass
spectrometer. Analytical reversed-phase HPLC was performed on a COSMOSIL 5C18-PAQ
Waters column (4.6 mm I. D. × 250 mm) eluted with water/methanol (flow rate, 1 mL/min; 220
nm UV detection) at room temperature. Preparative reversed-phase HPLC was performed on a
COSMOSIL 5C18-PAQ Waters column (10 mm I. D. × 250 mm) at room temperature. Column
chromatography was performed with silica gel (40-63 μm; Silicycle), C18 120 Å reversed-phase
silica gel (RP-18; 50 μm; YMC), and Sephadex LH-20 (GE Healthcare Bio-Science AB). Fractions
were monitored by TLC and spots were visualized by heating silica gel plates sprayed with 10%
H2SO4 in ethanol.
Hepatoprotective activity assay
Human HepG2 hepatoma cells were cultured in DMEM medium supplemented with 10%
fetal calf serum, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37 °C in a humidified
atmosphere of 5% CO2 +95% air. The cells were then passaged by treatment with 0.25% trypsin
in 0.02% EDTA. The MTT assay was used to assess the cytotoxicity of test samples. The cells
were seeded in 96-well multiplates. After an overnight incubation at 37 °C with 5% CO2, 10 μM
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test samples and APAP (final concentration of 8 mM) were added into the wells and incubated for
another 48 h. Then 100 μL of 0.5 mg/mL MTT was added to each well after the withdrawal of the
culture medium and incubated for an additional 4 h. The resulting formazan was dissolved in 150
μL of DMSO after aspiration of the culture medium. The plates were placed on a plate shaker for
30 min and read immediately at 570 nm using a microplate reader.142
Extraction and purification
The air-dried and powdered roots of Kadsura longipedunculata (34.0 kg) were percolated
with 95% aqueous ethanol (48 L) at room temperature. The combined extract was concentrated in
vacuo to yield a residue (2400 g). The residue (2400 g) was subjected to silica gel (200-300 mesh,
2400 g) column chromatography, eluting with a petroleum ether/acetone gradient system (100:1,
50:1, 10:1, 5:1, 3:1, 1:1), acetone, and 80% aqueous ethanol, to give fractions 1-15. Fraction 13
was chromatographed on an ODS (octadecylsilyl) column eluted with a gradient of water/methanol
(4:6 ~ 1:9) to yield four subfractions A-D. Fraction B was further chromatographed on a silica gel
column eluted with a gradient of chloroform/methanol (60:1, 50:1, 30:1, 20:1) and pure methanol
to yield five fractions B1-B5. Fraction B4 was purified by semi-preparative HPLC (60%
methanol/water), to give micrandilactone I (1, 7 mg). Fraction 14 was partitioned between water
and ethyl acetate. The ethyl acetate extract (60 g) was chromatographed on an ODS column eluted
with a gradient of water/methanol (4:1, 3:2, 2:3, 1:4) and pure methanol to yield five fractions AE. Fraction D was chromatographed on Sephadex LH-20 (eluted with chloroform/methanol) to
give five subfractions D1-D5. Fraction D1 (1.7 g) was subjected to silica gel (200-300 mesh, 3 g)
column chromatography, eluting with a chloroform/methanol gradient system (20% ~ 80%
methanol) to afford nine subfractions, D1.1-D1.9. Fraction D1.3 (365 mg) was purified by semipreparative HPLC (46% methanol/water), to give micrandilactone J (2, 164 mg) and 22, 23-di-epi83

micrandilactone J (3, 1 mg), micrandilactone H (4, 2mg), Fraction D1.5 (427mg) was purified by
semi-preparative HPLC (62% methanol/water) to give Kadsuraols A (5, 2mg), Kadsuraols B (6,
1mg), Kadsuraols C (7, 1mg).
Result and discussion.
Micrandilactone I (1) was obtained as white crystals. Its molecular formula was established
as C30H44O7 by the HRESIMS ion at m/z 539.2994 [M +Na]+ (calcd 539.2979), suggesting nine
indices of hydrogen deficiency. The 1H,

13

C, and HSQC NMR data of micrandilactone I (1)

indicated the presence of two ester carbonyls, six methyl, eight methylene, eight methine (one
olefinic and three oxygenated), and six non-protonated carbons (one olefinic and three oxygenated).
The 1H NMR spectra revealed three resonances at δH 4.27, 2.98, and 2.75, representing the ABX
spin system of H-1, H-2α, H-2β, respectively, one olefinic proton (δH 6.43), three oxygenated
methines (δH 4.50, 4.31, and 4.27), one methyl doublet (δH 0.97), five methyl singlets (δH 1.90,
1.56, 1.26, 1.10, and 0.93), and several methylene protons between δH 1.30 and 2.85. The 1D NMR
data and indices of hydrogen deficiency of micrandilactone I (1) suggested that it was a highly
oxygenated 3, 4: 9, 10-disecocycloartane containing six rings 143. Additionally, HMBC cross-peaks
of H-27 (δH 1.90) with C-24, C-25, and C-26 at δC 140.0, 128.0 and 166.2, respectively, and of H24 at δH 6.43 with C-22, C-23, C-26 and C-27 at δC 80.4, 23.7, 166.2, and 17.2, respectively,
revealed the presence of an α-methyl-α, β-unsaturated-γ-lactone moiety. These 1D and 2D NMR
data indicated that micrandilactone I (1) had a structure closely similar to that of kadcoccilactone
A 144, but with a hydroxy group located at C-15, instead of at C-17. Crystals of X-ray diffraction
quality of micrandilactone I (1) were obtained from methanol/water. The structure and absolute
configuration were unambiguously determined as (1R, 5S, 8S, 9S, 10R, 14R, 15S, 17R, 20S, 22S,
23S) by X-ray crystallographic analysis (Fig. 36) based on resonant scattering of only light atoms
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in both Mo and Cu radiations. Accordingly, the structure of micrandilactone I (1) was established
as shown in Fig. 34.
Micrandilactone J (2) was obtained as white crystals. Its molecular formula was established
as C29H42O9 by the HRESIMS ion at m/z 557.2740 [M+Na]+ (calcd 557.2740. Micrandilactone J
(2) is an isomer of micrandilactone C, based on comparison of their 1D NMR and MS data.
Crystals of X-ray diffraction quality of micrandilactone J (2) were obtained from methanol/water.
The resulting data unambiguously permitted the assignment of its relative configuration (Fig. 35).
The negative Cotton effect around 220 nm in the ECD spectrum indicated the (23S) absolute
configuration of the 3-methylfuran-2(5H)-one moiety based on comparison with the calculated
ECD spectrum (Fig. 38) as well as reported data145. Fig. 38 depicts overlays of the experimental
spectrum of compound 2, the average calculated spectrum of (23S)-2 and the Boltzmann-weighted
ECD spectrum of the major conformer 2a (60.17% Boltzmann population) using B3LYP/6‐
311++G(2d,p). The calculated ECD spectrum of compound (23S)-2 shows Cotton effects
characteristic of π →π* electronic transition at 221.26 nm region (Fig. 38). The electronic
transitions from MO139, MO140 and MO141 (H-3) to MO145 (LUMO) involving a π→ π*
transition of the enoate chromophore show negative rotatory strengths at 221.26 nm in (23S)-2
(conformer 2a), which is consistent with the strong negative Cotton effect at 217 nm in the
experimental ECD spectrum of 2. These results match well with the experimental ECD curve and
support the assignment of the absolute configuration of compound 2 as (1R, 5S, 8R, 9S, 10R, 13R,
14S, 15S, 17R, 20S, 22S, 23S). In addition, 1H and
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C NMR chemical shift calculations were

performed to assign the relative configurations of compounds 2 (1R, 5S, 8R, 9S, 10R, 13R, 14S,
15S, 17R, 20S, 22S, 23S) and 2′ (1S, 5R, 8S, 9R, 10S, 13S, 14R, 15R, 17S, 20R, 22R, 23S)
considering (23S) absolute configuration based on ECD. We used the gauge including atomic
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orbital (GIAO) method at the PCM/B3LYP/ 6–311+G(d,p) level of theory for DP4+ calculations.
The computed chemical shifts of 2 and 2′ (Fig. 41) were compared with the experimental values
utilizing DP4+ probability analyses. The latter yielded the structure of 2 with 100% probability,
leading to unequivocal assignment of (23S) absolute configurations for compound 2. Combining
the relative configuration assigned via the X-ray diffraction data, the comparison of experimental
and ab initio computed ECD spectra, and the DP4+ analysis, the absolute configuration of
micrandilactone J (2) was unequivocally defined as (1R, 5S, 8R, 9S, 10R, 13R, 14S, 15S, 17R, 20S,
22S, 23S). JBCA data were utilized in an attempt to determine the relative configurations at C-23,
C-22, and C-20. This method was applied to analyze the relative configurations of
polyhydroxylated acyclic molecules by detailed analysis of the 3JH, H and 2, 3JC, H values.141 The
“small” values (0 Hz) of 3J H-23, H-22 and 3J H-22, H-20 of micrandilactone J (2) indicated a
structure without significant conformational changes, thus giving reliable JBCA data.138 The
gauche orientations of H-22/H- 23, H-22/H-20, H-23/C-20, H-22/C-24 and H-20/C-23 were
evidence of the small 3J H-22, H-23, 3J H-22, H-20, 3J H-23, C-20, 3J H-22, C-24, and 3J H-20,
C-23, respectively, and the anti H-22/C-17 orientations gave large 3J H- 22, C-17 values. These
interactions established the relative configurations of C-23–C-20 as depicted in Fig. 42.
22, 23-Di-epi-micrandilactone J (3) had a molecular formula, C29H42O9, based on
HRESIMS analysis ([M+Na]+ m/z 557.2722) and its 13C NMR spectrum, indicative of it being an
isomer of micrandilactone J (2). The 1D NMR data and index of hydrogen deficiency also
suggested a highly oxygenated schiartane-type nortriterpenoid possessing six rings 42. Analysis of
the 2D NMR data (Fig. 39 and 40) showed an identical 2D structure compared to micrandilactone
J (2). The overlaid HSQC spectra of 2 and 3 showed highly coincidental cross-peaks of the fused
5/5/7/6/5 ring systems (Fig. 40), which indicated that micrandilactone J (2) and 22, 23-di-epi-
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micrandilactone J (3) had identical pentacyclic core structures. The misalignment of cross-peaks
combined with the opposite Cotton effect near 220 nm in the ECD spectrum indicated that 3 and
2 had opposite absolute configurations at some of the stereocenters. The absolute configuration of
C-23 was assigned as R based on the positive Cotton effects at 217 nm in the ECD spectrum.144
The absolute configurations of the remaining stereocenters of compound 3 were established via Jbased configuration analysis.
The absolute configurations of the stereogenic centers of the side chain of 22,23-di-epimicrandilactone J (3) were deduced from the JBCA, combined HSQC overlay with 2, NOESY, as
well as ECD data. The positive Cotton effect around 220 nm in the ECD spectrum indicates its
(23R) absolute configuration.146 JBCA data were utilized to determine the relative configurations
at C-23, C-22, C-20 as was described for micrandilactone J (2).141 The gauche orientations of H22/H-23, H-22/H-20, H-22/C-17, and H-20/C-23 were suggested by the small 3J H-22, H-23, 3J
H-22, H-20, 3J H-22, C-17, and 3J H-20, C-23 values, respectively, and the anti-orientation of H22/C-24 by a large 3J H-22, C-24 value, and thus the relative configurations of C-22 and C-20
were as depicted in Fig. 42. However, due to the absence of key 3J C-20, H-23 and 2J C-22, H-23
couplings, the relative configurations of C-23 and C-22 as shown in Fig. 42 could not be
differentiated. Also, because of the complex splitting pattern of H-17, the key 3J H, H values were
unavailable. Such an absence of coupling constant data presented a significant challenge for
assignment of the absolute configuration of C-22, C-20, and C-17, because NOE data could not be
applied to associate the stereogenic carbons with a proton attached to the rigid ring system. Thus,
the HSQC method combined with JBCA and NOESY data of a degassed sample were applied to
define the absolute configuration of the remaining stereogenic carbons. The small 3J H-22, H-23,
3

J H-22, C-17, 3J H-20, C-23, and 3J H-20, H-22 values (Fig. 42) of 22,23-di-epi-micrandilactone
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J (3) indicated that rotation of the C-17–C-23 moiety is restricted. Thus, NOESY data of a degassed
sample could be applied to determine the relative configuration of the H-17–H-23 stereocenters.
The correlation of H-23/H-22, H-22/H-20, and H-21/H-17 indicated (17R, 20S, 22R) absolute
configuration. The NOESY data for C-20 and C-17 were also supported by the JBCA data. H-N
HSQC overlay is frequently applied to monitor the binding and conformational changes of proteins
based on the peak shift.147 Herein, H-C HSQC overlay was used to compare the configurations of
2 and 3. In the overlaid HSQC spectrum of 2 and 3, the C-1, C-5, C-8, and C-17 resonances of the
two isomers are completely overlapped, indicating that they have the same relative configurations
(Fig. 40). For the non-protonated stereogenic carbons, the signals of the adjacent carbons could be
used to determine their relative configurations. The cross-peaks of C-1, C-8, C-15, and C-17 are
completely overlapped, suggesting that C-10, C-9, C-14, and C-13 of 2 and 3 had the same relative
configurations (Fig. 40). This is consistent with the results of the NOESY experiment (Fig. 42).
Combined with the (17R) absolute configuration, the absolute configuration of 22, 23-di-epimicrandilactone J (3) was assigned as (1R, 5S, 8R, 9S, 10R, 13R, 14S, 15S, 17R, 20S, 22R, 23R)
(Fig. 34). The peak shifts of C-23 on the HSQC overlay spectra of the two isomers indicated
different configurations, matching the opposite Cotton effects in the ECD spectra of the two
compounds. However, the different C-23 configuration of the two compounds will influence the
HSQC overlay results of C-20 and C-22 (Fig. 40). Thus, the absolute configurations of C-20 and
C-22 could not be elucidated from the developed HSQC method.
Micrandilactone H (4) was isolated as colorless crystals, and gave an [M + Na]+ ion at m/z
539.2637 in the HRESIMS, consistent with a molecular formula of C29H40NaO8 (calcd 539.2615),
indicating nine indices of hydrogen deficiency. The 13C and HSQC NMR spectra) revealed two
lactone carbonyls resonating at δC 175.9 and 175.1; two olefinic functionalities with four carbon
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resonances at δC 147.7, 120.9, 148.9 and 130.5; four sp3 non-protonated carbons (three oxygenated)
resonances at δC 99.7, 85.2, 70.8 and 52.8; eight sp3 methine (three oxygenated) resonances at δC
82.5, 59.6, 58.8, 77.1, 43.3, 44.3, 74.9 and 83.0 ppm; six sp3 methylene resonances at δC 46.0,
42.7, 40.4, 36.9, 28.7, and 25.3; and five methyl resonances at δC 29.9, 26.6, 23.5, 16.1, and 10.9.
The 1H-NMR spectra revealed an ABX spin system, with δH 4.27 (d, J = 4.5 Hz), 2.94 (dd, J =
18.0, 4.5 Hz) and 2.72 (d, J = 18.0 Hz), which were assigned to H-1, H-2α and H-2β, respectively,
together with four methyl singlets at δH 1.83 (3H, s), 1.27 (3H, s), 1.14 (3H, s), 1.12 (3H, s); one
methyl doublet at δH 1.34 (3H, d, J = 7.0 Hz); two olefinic protons (δH 7.23, 5.76); four methine
protons (δH 5.27, 4.00 and 3.31); and several methylene protons between δH 1.22 and 2.80.
According to these data, micrandilactone H is a schiartane-type nortriterpenoid whose structure is
similar to micrandilactone C, except for an extra double bond, one less hydroxy group and the
different location of the C-18 methyl group.144 The HMBC cross-peaks of H-18 with C-8, C-13,
C-14 and C-15, H-11 with the C-8, C-9, C-12, C-13 and C-19, and H-12 with C-9, C-14 and C-17
indicated that Me-18 was connected at C-14 and the double bond was located at C-12 and C-13.
Thus, the 2D structure of micrandilactone H was established as shown in Fig. 34. The structure
and absolute configuration were unambiguously determined as (1R, 5S, 8S, 9S, 10R, 14R, 15S,
17R, 20S, 22S, 23S) by X-ray crystallographic analysis (Fig. 37) based on resonant scattering of
only light atoms in both Mo and Cu radiations. These results matched the assignment of the (23S)
absolute configuration based on the negative Cotton effect at 214 nm in the ECD spectrum.146 The
molecular structure features an intramolecular hydrogen bond between the 15- and 9-OH groups.
However, the 22-OH group does not form an intramolecular hydrogen bond with the adjacent
lactone carbonyl, instead forming an intermolecular hydrogen bond with the C-3 lactone carbonyl.
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Micrandilactone H: Colorless crystals; ESIMS (m/z): 539 [M + Na]+;HRESIMS (m/z):
539.2637 [M + Na]+ (calcd 539.2615 for C29H40NaO8), 1H-NMR (500Hz, pyridine-d5), 4.27 (d,
4.5, H-1), 2.72 (d, 18.0, H-2α), 2.94 (dd, 18.0, 4.5, H-2β), 2.57 (dd, 13.0, 4.0, H-5), 1.69
(overlapped, H-6α), 1.31 (overlapped, H-6β), 2.37 (m, H-7α), 2.07 (overlapped, H-7β), 1.72
(overlapped, H-8), 2.35 (m, H-11α), 2.26 (m, H-11β), 5.76 (d, 7.0, H-12α), 4.00 (s, H-15), 2.30
(m, H-16α), 2.11 (dd, 8.5, 3.0, H-16β), 3.31 (m, H-17), 1.12 (s, H-18), 2.15 (d, 15.0, H-19α), 2.02
(d, 15.0, H-19β), 2.21(m, H-20), 1.34(d, 7.0, H-21), 4.00 (s, H-22), 5.27 (brs, H-23), 7.23 (s, H24), 1.83 (s, H-27), 1.27 (s, H-29), 13C-NMR (500Hz, pyridine-d5), 82.5 (C-1), 36.9 (C-2), 175.9
(C-3), 85.2 (C-4), 59.6 (C-5), 28.7 (C-6), 25.3 (C-7), 58.8 (C-8), 70.8 (C-9), 99.7 (C-10), 42.7 (C11), 120.9 (C-12), 147.7 (C-13), 52.8 (C-14), 77.1 (C-15), 40.4 (C-16), 43.3 (C-17), 26.6 (C-18),
46.0 (C-19), 44.3 (C-20), 16.1 (C-21), 74,9 (C-22), 83.0 (C-23), 148.9 (C-24), 130.5 (C-25), 175.1
(C-26), 10.9 (C-27), 29.9 (C-28), 23.5 (C-29).
Figure 36. ORTEP drawing of micrandilactone I (1).

Figure 35. ORTEP drawing of

micrandilactone J (2).

Figure 37. ORTEP drawing of micrandilactone H (4).

90

Figure 38. Experimental ECD spectrum of compound 2 (black), calculated averaged Boltzmann weighted
ECD spectra of conformers (2a–2c and 2e) (green), and ECD spectrum of conformer 2a (major conformer)
in MeOH (red). σ-value (artificial line broadening) was set to 0.16 eV.

Figure 39. Key HMBC (A) correlations of micrandilactone I (1); HMBC (B) COSY (C), NOESY (D)
correlations of 22, 23-di-epi-micrandilactone J (3); and NOESY (E) correlations of micrandilactone J (2).
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Figure 40. (A) Entire HSQC overlay. The black parts of the structures are identical and the blue parts are
different based on the HSQC data. Key non-overlaid HSQC crosspeaks of micrandilactone J (2) and 22,23di-epi-micrandilactone J (3) are shown.
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Table 5. 1H and

13

C NMR data for micrandilactone I (1), micrandilactone J (2) and 22, 23-di-epi-

micrandilactone J (3) in pyridine-d5 using an INOVA-500 MHz spectrometer.

no.

1

2

3

δH

δC

δH

δC

δH

δC

1

4.27 (d, 5.0)

81.8

4.28 (d, 4.5)

82.4

4.30 (d, 4.5)

82.4

2α

2.75 (d, 17.5)

36.5

2.71 (d, 17.5)

37.3

2.73 (m)

37.3

2β

2.98 (dd, 17.5, 5.0)

2.95 (dd, 17.5, 4.5)

2.94 (dd, 18.0, 4.5)

3

175.2

176.0

176.0

4

84.8

85.3

85.4

5

2.55 (dd, 13.5, 4.0)

60.0

2.70 (dd, 13.5, 3.5)

59.0

2.70 (overlapped)

59.0

6α

1.63 (m)

28.8

1.75 (overlapped)

28.9

1.74 (m)

29.0

6β

1.32 (br t, 13.5)

7α

2.82 (dd, 14.0, 9.0)

7β

2.08 (overlapped)

1.29 (overlapped)
24.6

2.69 (overlapped)
2.19 (overlapped)

1.29 (overlapped)
24.7

2.71 (overlapped)

24.8

2.19 (m)
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8

1.84 (overlapped)

53.9

2.00 (br d, 11.0)

57.0

2.02 (br d, 11.0)

56.9

9

73.8

72.4

72.3

10

100.3

100.0

100.0

11α

2.11 (overlapped)

11β

1.70 (br d, 13.0)

12α

2.22 (overlapped)

12β

1.46 (br d, 13.0)

39.5*

1.88 (m)

38.6

1.63 (br d, 14.0)
30.6

2.79 (m)

1.90 (m)

38.7

1.65 (overlapped)
39.3

1.71 (br d, 14.0)

2.80 (t, 12.5)

39.3

1.67 (overlapped)

13

46.9

46.1

46.1

14

50.9

87.0

86.8

15

4.30 (dd, 10.0, 5.0)

76.7

4.48 (s)

77.2

4.49 (s)

77.4

16α

1.99 (overlapped)

39.4*

2.53 (overlapped)

36.5

2.53 (m)

35.9

16β

1.81 (overlapped)

17

1.79 (overlapped)

44.8

2.53 (overlapped)

54.6

2.53 (overlapped)

54.9

18

0.93 (s)

15.5

1.48 (s)

18.6

1.48 (s)

18.7

19α

2.03 (d, 5.0)

48.0

2.05 (d, 15.5)

47.7

2.07 (d, 15.0)

47.8

19β

2.05 (d, 5.0)

20

2.05 (overlapped)

39.3*

2.57 (m)

38.1

2.38 (m)

37.3

21

0.97 (d, 6.5)

13.7

1.32 (d, 6.0)

18.8

1.22 (d, 7.0)

18.9

22

4.50 (dt, 13.0, 3.0)

80.4

4.06 (br s)

73.9

4.31 (overlapped)

73.8

23α

2.18 (overlapped)

23.7

5.26 (s)

83.0

5.24 (s)

83.5

23β

1.97 (overlapped)

24

6.46 (d, 6.0)

140.0

7.19 (overlapped)

148.8

7.39 (br s)

147.8

2.18 (overlapped)

2.25 (m)

2.13 (d, 15.5)

2.14 (d, 15.0)

25

128.0

130.4

131.0

26

166.2

175.1

174.7

27

1.90 (s)

17.2

1.81 (s)

10.9

1.85 (s)

11.0

28

1.56 (s)

13.0

29

1.10 (s)

22.9

1.29 (s)

30.3

1.29 (s)

30.3

30

1.26 (s)

29.4

1.08 (s)

23.9

1.08 (s)

23.9
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Figure 41. DP4+ analysis outcome using the Excel spreadsheet available for free at sarottiNMR.weebly.com. Isomer 1 and Isomer 2 represents (2a) and (2b) of compound 2, respectively; Gibbs free
energy-based calculation outcomes were used for the analysis.
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A: C-23~C-22 of micrandilactone J (2)

C: C-23~C-22 of 22, 23-di-epi-micrandilactone J (3)

E

3

JH-23, H-22

Measured data

Predicted data

Gauche: 0 (small)

Gauche 0-3 (small)

a

3

JH-23, H-22

b

F
Measured data

Predicted data

Gauche: 0 (small)

Gauche 0-3 (small)

Anti 7-10 (large)
3

JH-23, C-20

Gauche: 3.1(small)

Gauche 1-3 (small)

Anti 7-10 (large)
3

JH-23, C-20

Not observed

Anti 5-7 (large)
3

JH-22, C-24

Gauche: 2.6 (small)

Gauche 1-3 (small)

Anti 5-7 (large)
3

JH-22, C-24

Anti: 6.0 (large)

Anti 5-7 (large)
2

JH-23, C-22

Anti: 2.0 (small)

Gauche -4 to -6 (large)

Gauche 1-3 (small)

Gauche 1-3 (small)
Anti 5-7 (large)

2

JH-23, C-22

Not observed

Gauche -4 to -6
(large)

Anti 2-0 (small)

Anti 2-0 (small)
2

JH-22, C-23

Anti: 1.9 (small)

Gauche -4 to -6 (large)
Anti 2-0 (small)

2

JH-22, C-23

Gauche: -4.2 (large)

Gauche -4 to -6
(large)
Anti 2-0 (small)

B: C-22~C-20 of micrandilactone J (2)

D: C-22~C-20 of 22, 23-di-epi-micrandilactone J (3)
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G

3

JH-22, H-20

Measured data

Predicted data

Gauche: 0 (small)

Gauche 1-4 (small)

H

3

JH-22, H-20

Measured data

Predicted data

Gauche: 0 (small)

Gauche 1-4 (small)

Anti 8-11 (large)
3

JH-22, C-17

Anti: 6.4 (large)

Gauche 1-3 (small)

Anti 8-11 (large)
3

JH-22, C-17

Gauche: 3.4 (small)

Anti 6-8 (large)
3

JH-20, C-23

Gauche: 3.1 (small)

Gauche 1-3 (small)

Anti 6-8 (large)
3

JH-20, C-23

Gauche: 3.4 (small)

Anti 6-8 (large)
2

JH-20, C-22

2

JH-22, C-20

Anti: 2.5 (small)

Anti: 2.7 (small)

Gauche -5 to -7

Gauche 1-3 (small)

Gauche 1-3 (small)
Anti 6-8 (large)

2

JH-20, C-22

Anti: -2.6 (small)

Gauche -5 to -7

(large)

(large)

Anti 1-2 (small)

Anti 1-2 (small)

Gauche -5 to -7

2

JH-22, C-20

Not observed

Gauche -5 to -7

(large)

(large)

Anti 1-2 (small)

Anti 1-2 (small)

Figure 42. Rotamers and coupling constants for C-23–C-22(A), C-22–C-20 (B) of 2, C-23–C-22(C), C22–C-20 (D) of 3. Key NOESY correlations of 2 (E), (G), and 3 (F), (H).

Kadsuraol A (5), obtained as yellow crystals, EtOH); mp 154−157 °C; had the molecular
formula C27H30O9 as determined by positive HRESIMS (m/z 521.1784 [M + Na]+, calcd. 521.1782)
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and 13C NMR data, indicating 13 indices of hydrogen deficiency. Its UV bands (218 and 270 nm)
and IR absorptions (1712 and 1616 cm−1) indicated the presence of carbonyl and benzene
functionalities. The 1H NMR data (Table 2) displayed an aromatic proton singlet at δH 6.61, two
singlets characteristic of a methylenedioxy group at δH 6.00 and 5.93 (br s), an olefinic proton
signal at δH 5.86 (br q, J = 7.0 Hz), an AB quartet at δH 4.59 and 4.54 (d, J = 10.0 Hz), and two
enolic methoxy singlets at δH 4.09 (3H) and 3.68 (3H). In the highfield region, a methylene (δH
1.90, dd, J = 11.0 and 13.0 Hz, and 1.48, dd, J = 7.0 and 13.0 Hz, respectively), a methine (δH 1.59,
m), and four methyl groups [δH 1.84 and 0.99 (each 3H, d, J = 7.0 Hz), 1.71 and 1.12 (each 3H, s)]
were observed. The 13C NMR spectrum revealed 27 carbon resonances. The 1H and 13C NMR data
(Table 2), and the HSQC spectrum exhibited the presence of an α,β-unsaturated carbonyl carbon
(δC 193.9), an ester carbonyl carbon (δC 167.7), a pentasubstituted aromatic moiety (δC 102.9,
124.3, 124.9, 130.5, 142.2, and 150.3), four olefinic carbons (δC 128.3, 135.3, 137.0, and 160.6),
a methylenedioxy carbon (δC 101.5), an oxymethylene carbon (δC 81.9), two oxymethine carbons
(δC 72.7 and 75.6), two O-methyl groups (δC 59.6 and 60.3), three quaternary carbons (δC 56.6,
45.7, and 46.2), a methylene group (δC 31.8), a methine group (δC 29.9), and four methyl groups
(δC 20.2, 16.9, 15.5, and 14.1). Analysis of the 1D and 2D NMR data assigned a C18 skeleton
comprising two C6·C3 constituent units for 5. The HMBC cross-peaks from H-6′ to C-1′, C-2′,
and C-7′, H-7 to C-2 and C-6, H2-7′ to C-1′, C-2′, C-6′, C-8′, and C-9′, H3-9 to C-8′, C-7, and C8, and especially H3-9 and H-7 to C-1′ (green). Crystallization of Kadsuraols A (5) from MeOH:
H2O (10:1) afforded yellow crystals of the hemihydrate suitable for X-ray crystal structure studies.
Data at T = 100 K with Mo Kα radiation yielded R = 0.053 and a Flack parameter x = 0.2 (2), in
agreement with the (7S, 8S, 1′S, 2′S, 6′R, 8′R) absolute configuration. In the crystalline hemihydrate,
there are eight independent (unrelated by symmetry) molecules of 5, one of which is shown in Fig.
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43, and four water molecules. The eight molecules differ somewhat in conformation, particularly
for the two methoxy groups, and one of the eight exhibits disorder. In addition, 1H and 13C NMR
chemical shift calculations were performed to assign the absolute configuration of compounds 5
(7S, 8S, 1′S, 2′S, 6′R, 8′R), and three other diastereomers labeled 5′ (7S, 8S, 1′S, 2′R, 6′R, 8′R), 5′′
(7R, 8S, 1′S, 2′R, 6′R, 8′R) and 5′′′ (7S, 8S, 1′S, 2′R, 6′S, 8′R) considering the positions that are
readily epimerizable such as allylic alcohols, and protons near to carbonyl moieties and esters. We
used the gauge independent atomic orbital (GIAO)87-89 method at the PCM/mPW1PW91/6–
311+G(d,p) level of theory89 for DP4+ calculations.90 The computed chemical shifts of 5, 5′, 5′′,
and 5′′′ were compared with the experimental values utilizing total absolute deviation (TAD),
mean absolute error (MAE) and DP4+ probability analyses; all three methods have been
successfully applied in addressing stereochemical assignment of isomeric compounds.148-149 The
TAD and MAE values for 1H NMR and 13C NMR chemical shifts were in accordance, and clearly
pointed out 5 as the most probable stereoisomer (Fig. 46). DP4+ analysis also predicted the
structure of 5 to match the experimental results with 100% probability (Fig. 46). Considering the
relative configuration assigned via the X-ray diffraction data, the comparison of experimental and
ab initio computed ECD spectra, and the DP4+ analysis, the absolute configuration of 5 was
unequivocally defined as (7S, 8S, 1′S, 2′S, 6′R, 8′R). Kadsuraol B (6) white powder, Kadsuraol C
(7) white powder, 6 and 7 were assigned molecular formulas of C29H28O9 and C24H26O9,
respectively, on the basis of the sodium adduct HRESIMS ions at m/z 543.1626 and 481.1469 and
13

C NMR data. The HSQC overlay (see Figures 47 and 48) showed 6 and 7 were similar to 5

except for the C-7 substituents. The 9- angelate group in 5 was replaced by a benzoate and an
acetoxy group in 6 and 7, respectively. The structures of 6 and 7 were confirmed via comparison
of 1H, 13C NMR, and ECD data with those of 5.
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Kadsuraol B (6) white powder, [𝛼]20
D +62 (c = 1, MeOH); Kadsuraol C (7) white powder,
[𝛼]20
D +58 (c = 1, MeOH); IR (KBr) νmax 3430, 2959, 1712, 1654, 1616, 1459, 1419, 1395, 1354,
1331, 1236, 1190, 1115, 1109, 1058, 1020, 964, 937, 903, 846, 786, 756 cm-1; 6 and 7, were
assigned molecular formulas of C29H28O9 and C24H26O9, respectively, on the basis of the sodium
adduct HRESIMS ions at m/z 543.1626 and 481.1469 and 13C NMR data. The HSQC overlay (Fig.
47 and 48) showed 6 and 7 were similar to 5, except for the C-7 substituents. The 9-angelate group
in 5 was replaced by a benzoate and an acetoxy group in 6 and 7, respectively. The structures of 6
and 7 were confirmed via comparison of 1H, 13C NMR, and ECD data with those of 5.
Compounds 1–7 were evaluated for their in vitro hepatoprotective activities against N-acetyl-paminophenol (APAP)-induced toxicity in HepG2 cells by means of the MTT method.142
Compounds 1, 3, 4, and 5 showed moderate hepatoprotective activity by integrated analysis against
APAP-induced toxicity in HepG2 cells (Table 7).
Four new highly oxygenated triterpenoids and three novel dibenzocyclooctadiene lignans were
isolated from Kadsura longipedunculata. Their 2D structures were solved using NMR and
HRESIMS data and their absolute configurations were elucidated using X-ray diffraction analysis,
ECD experimental results compared to ab initio computed spectra, HSQC overlay, DP4+, NOESY,
and J-based configuration analysis. This is the first comprehensive stereochemical assignment of
a non-crystalline schiartanetype nortriterpenoid. This general protocol may contribute towards
solving the problems hampering the assignment of the absolute configurations of other members
of this class of nortriterpenoids. Compounds 1, 3, 4, and 5 showed moderate hepatoprotective
activity against APAP-induced toxicity in HepG2 cells with cell survival rates of 53.0 and 50.2%,
respectively, at 10 μM (bicyclol, 49.0%), while compound 2 was inactive.
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Figure 43. Key HMBC correlations of 5.

Figure 44. The optimized conformation and the key ROESY correlations of 5.
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Figure 45. X-ray ORTEP drawing of 5 revealing an unusual crystal packing (A) with eight structures in
the unit cell (B).
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DP4+

TAD

MAE

DP4+

TAD

MAE

Proton

100%

2.46

0.14

Proton

0.0%

6.42

0.38

Carbon

100%

109.16

4.04

Carbon

0.0%

154.44

5.72

Both

100%

111.63

4.18

Both

0.0%

160.86

6.10

DP4+

TAD

MAE

DP4+

TAD

MAE

Proton

0.0%

5.10

0.30

Proton

0.0%

7.96

0.47

Carbon

0.0%

139.30

5.16

Carbon

0.0%

148.65

5.51

Both

0.0%

144.40

5.46

Both

0.0%

156.61

5.98

Figure. 46. Total absolute deviation (TAD), mean absolute error (MAE) and DP4+ probability analyses
(sarotti-NMR.weebly.com) for 5 and three of its diastereomers (Gibbs free energies at the
PCM/mPW1PW91/6–311+G(d,p) level were used for the analysis).
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Table 6. 1H NMR Data of 5-7 in CDCl3, δ in ppm (J in Hz, 500 MHz).
no.
6
7
9
6′
7′α
7′β
8′
9′
19α
19β
20α
20β
2′′
3′′
4′′
5′′
6′′
7′′
4′-OCH3
5′-OCH3

5
6.61 (s)
5.38 (s)
1.12 (s)
4.52 (s)
1.90 (dd, 11.0, 13.0)
1.48 (dd, 7.0, 13.0)
1.59 (m)
0.99 (d, 7.0)
6.00 (br s)
5.93 (br s)
4.59 (d, 10.0)
4.54 (d, 10.0)

6
6.62 (s)
5.62 (s)
1.15 (s)
4.55 (s)
1.95 (dd, 11.0, 13.0)
1.52 (dd, 7.0, 13.0)
1.68 (m)
1.02 (d, 7.0)
6.00 (br s)
5.90 (br s)
4.65 (d, 10.0)
4.59 (d, 10.0)

5.86 (br q, 7.0)
1.84 (d, 7.0)
1.71 (s)

7.92 (br d, 7.0)
7.35 (t, 7.0)
7.47 (dt, 1.5, 7.0)
7.35 (t, 7.0)
7.92 (br d, 7.0)
3.78 (s)
4.12 (s)

3.68 (s)
4.09 (s)

7
6.55 (s)
5.22 (s)
1.13 (s)
4.51 (s)
1.90 (dd, 11.0, 13.0)
1.48 (dd, 7.0, 13.0)
1.56 (m)
0.97 (d, 7.5)
6.00 (d, 1.5)
5.92 (d, 1.5)
4.62 (d, 10.0)
4.52 (d, 10.0)
1.87(1H, s)

3.76 (s)
4.13 (s)
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Table 7. Hepatoprotective effect of compounds 1, 3, 4 and 5 (10 μM) against APAP-induced toxicity in
HepG2 cell.

OD (mean ±SD)

Cell survival rate (% of
normal)

Control

1.276±0.197

100.00

APAP 8mM

0.494±0.111

27.64

1

0.710±0.032

52.0

3

0.585±0.014

56.84

4

0.641±0.014

53.0

5

0.659 ± 0.023

48.22

Bicyclol

0.678±0.020

48.77
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Figure 47. The HSQC Overlay of of Compounds A (red) and B (gray)

Figure 48. The HSQC Overlay of of kadsuraols A (red) and C (green)
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Kadsuraols A–C (5–7)are likely biosynthesized via the phenylpropenoid pathway (Scheme
S1). Thus, one-electron oxidation of 3,4,5-trihydroxycinnamyl alcohol (6) would lead to formation
of the C-8 radical 7. Dirigent protein guided C-C radical coupling150 would afford the 8,8′-linked
quinone-methide 8 and subsequently the bis-phenylpropanol 9 via reduction. Phenol-oxidative
formation of the biphenyl bond would lead to the dibenzocyclooctadiene intermediate 10 that may
be susceptible to further oxidation and generation of the unique cyclobutane moiety in 12 via the
diradical 11. Various well-established functional group manipulations would transform 12 into the
target pentacyclic architecture 15 via intermediates 13 and 14. The appropriate acylations would
then convert 15 into the novel kadsuraols A–C (1–3). The putative biosynthesis pathway of
compound 1, 2 and 3 was represent in Scheme 2
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Scheme 2. Putative Biosynthesis Pathway Towards the Formation of 5–7.

Conclusion
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Natural products have provided a diversity of valuable drugs in addition to the identification of
key targets for the control of cancer. It has been estimated that up to 50% of all present day
therapeutics are derived from natural products, and in the case of cancer, the number is near 75%.
In this study, a series of compounds have been explored from natural resources including plants,
marine sponges and microbio. Their structures and absolute configurations were established using
a combination of MS, NMR, and electronic circular dichroism data and X-ray diffraction. These
compounds showed different activities related to human disease.

The orchestration of molecular ion networking and a set of computationally assisted structural
elucidation approaches in the discovery of a new class of pyrroloiminoquinone alkaloids that
possess selective bioactivity against pancreatic cancer cell lines. Aleutianamine represents the first
in a new class of pyrroloiminoquinone alkaloids possessing a highly strained multi-bridged ring
system, discovered from Latrunculia (Latrunculia) austini Samaai, Kelly & Gibbons, 2006 (class
Demospongiae, order Poecilosclerida, family Latrunculiidae) recovered during a NOAA deepwater exploration of the Aleutian Islands. The molecule was identified with the guidance of mass
spectrometry, nuclear magnetic resonance, and molecular ion networking (MoIN) analysis.
Importantly, we have isolated one of the unreported discorhabidins, aleutianamine, which shows
potent and selective cytotoxicity toward solid tumor cell lines including pancreatic cancer (PANC1) with an IC50 of 25 nM and colon cancer (HCT-116) with an IC50 of 1 μM, and represents a
potent and selective candidate for advanced preclinical studies. Aleutianamine is the dehydration
and rearrangement product of discorhabdin A (DA) which is the highest yielding discorhabdin in
Latrunculia sp. Several groups have already successfully synthesized discorhabdins including
discorhabdin A32. Due to a slow growth rate, difficulties in the collection of sponges and mass109

limited quantities of the drug lead, we will use synthetic methods to accumulate adequate amounts
of aleutianamine for cell biology and in vivo study. We have in hand 100 mg of DA isolated as a
co-occurring marine natural product during our investigations of these sponges. We hypothesize
that aleutianamine is a promising drug lead for pancreatic cancer and can be made available for
study by semi-synthesis from discorhabdin A. A proposed mechanism are shown below.

Scheme 3. Biotrasformation of discorhabdin A to aleutianamine.

Rapamycin

A prominent member of plant microbiomes, B. amyloliquefaciens cultured from American
sycamore produce rapamycin as shown by HR-LCMS, NMR, mass imaging (MI) and the Global
Natural Products Social (GNPS) network or molecular ion networking (MoIN). A metagenomics
and metabolomics of sycamore tissues revealed that the vegetative state of B. amyloliquefaciens
110

inhabits the xylem but not the healthy leaves, shown to be due to the high antibiotic concentration
in the leaves. Published results show that inhibiting TOR in plants will promote autophagy and
differentiation of xylem36, indicating that rapamycin from the microbiome play a role in the genesis
of vascular tissue by promoting differentiation of xylem. Thus rapamycin appears to play a
significant role vascularization of these tall trees that co-evolved along-side very tall herbivorous
reptiles. The studies presented here serve as a platform for the further exploration of the
biosynthesis pathway of ‘‘endogenous rapamycin’’ in the microbiology.

Figure 49. The experimental ECD spectrum of micrandilactone I (1).
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Figure 50. The HRESIMS spectrum of micrandilactone I (1).

Figure 51. The 1H-NMR spectrum of micrandilactone I (1).
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Figure 52. The 13C-NMR spectrum of micrandilactone I (1).

Figure 53. The HMBC spectrum of micrandilactone I (1).
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Figure 54. The HSQC spectrum of micrandilactone I (1).
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Figure 55. The experimental ECD spectrum of micrandilactone J (2).

Figure 56. The HRESIMS spectrum of micrandilactone J (2).
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Figure 57. The 1H-NMR spectrum of micrandilactone J (2).
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Figure 58. The 13C-NMR spectrum of micrandilactone J (2).
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Figure 59. The ROESY spectrum of micrandilactone J (2).
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Figure 60. HETLOC spectrum of micrandilactone J (2).

Figure 61. The experimental ECD spectrum of 22, 23-diastereoismomer-micrandilactone G (3).

Figure 62. The HR-ESI-MS spectrum of 22, 23-diastereoismomer-micrandilactone J (3).
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Figure 63. The 1H-NMR spectrum of 22, 23-diastereoismomer-micrandilactone J (3).
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Figure 64. The 13C-NMR spectrum of 22, 23-diastereoismomer-micrandilactone J (3).
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Figure 65. The HSQC spectrum of 22, 23-diastereoismomer-micrandilactone J (3).
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Figure 66. The HMBC spectrum of 22, 23-diastereoismomer-micrandilactone J (3).
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Figure 67. The ROESY spectrum of 22, 23-diastereoismomer-micrandilactone J (3).

Figure 68. HETLOC spectrum of 22, 23-diastereoismomer-micrandilactone J (3).
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Figure 69. The CD spectrum of Micrandilactone H

Figure 70. The HR-ESI-MS spectrum of Micrandilactone H
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Figure 71. The 1H-NMR spectrum of Micrandilactone H

Figure 72. The 13C-NMR spectrum of Micrandilactone H
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Figure 73. The HSQC spectrum of Micrandilactone H

Figure 74. The HMBC spectrum of Micrandilactone H
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Figure 75. The NOESY spectrum of Micrandilactone H

Figure 76. The HRESI Mass Spectrum of Kadsuraol A.
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Figure 77. The 1H NMR Spectrum of Kadsuraol A.
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Figure 78. The 13C NMR Spectrum of Kadsuraol A.
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Figure 79. The HSQC Spectrum of Kadsuraol A.

Figure 80. The HMBC Spectrum of Kadsuraol A.
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Figure 81. The ROESY Spectrum of Kadsuraol A.
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Figure 82. The Experimental ECD Spectrum of Kadsuraol A.

Figure 83. The HRESI Mass Spectrum of Kadsuraol B
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Figure 84. The 1H NMR Spectrum of Kadsuraol B.
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Figure 85. The 13C NMR Spectrum of Kadsuraol B.
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Figure 86. The HSQC Spectrum of Kadsuraol B.

Figure 87. The HSQC Overlay of of Kadsuraol A (red) and Kadsuraol B (gray)
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Figure 88. The HMBC Spectrum of Kadsuraol B.
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Figure 89. The ROESY Spectrum of Kadsuraol B.
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Figure 90. The Experimental ECD Spectrum of Kadsuraol B.

Figure 91. The HRESI Mass Spectrum of Kadsuraol C.
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Figure 92. The 1H NMR Spectrum of Kadsuraol C.
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Figure 93. The 13C NMR Spectrum of Kadsuraol C.
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Figure 94. The HSQC Spectrum of Kadsuraol C
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Figure 95. The HSQC Overlay of Kadsuraol A (red) and Kadsuraol C (green)
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Figure 96. The HMBC Spectrum of Kadsuraol C
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Figure 97. The ROESY Spectrum of Kadsuraol C
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Figure 98. The Experimental ECD Spectrum of Kadsuraol C.
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